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Résumé 
L’insomnie, commune auprès de la population gériatrique, est typiquement traitée avec 
des benzodiazépines qui peuvent augmenter le risque des chutes. La thérapie cognitive-
comportementale (TCC) est une intervention non-pharmacologique ayant une efficacité 
équivalente et aucun effet secondaire. Dans la présente thèse, le coût des benzodiazépines 
(BZD) sera comparé à celui de la TCC dans le traitement de l’insomnie auprès d’une 
population âgée, avec et sans considération du coût additionnel engendré par les chutes 
reliées à la prise des BZD. Un modèle d’arbre décisionnel a été conçu et appliqué selon la 
perspective du système de santé sur une période d’un an. Les probabilités de chutes, de 
visites à l’urgence, d’hospitalisation avec et sans fracture de la hanche, les données sur 
les coûts et sur les utilités ont été recueillies à partir d’une revue de la littérature. Des 
analyses sur le coût des conséquences, sur le coût-utilité et sur les économies potentielles 
ont été faites. Des analyses de sensibilité probabilistes et déterministes ont permis de 
prendre en considération les estimations des données.  
Le traitement par BZD coûte 30% fois moins cher que TCC si les coûts reliés aux chutes 
ne sont pas considérés (231$ CAN vs 335$ CAN/personne/année). Lorsque le coût relié 
aux chutes est pris en compte, la TCC s’avère être l’option la moins chère (177$ CAN 
d’économie absolue/ personne/année, 1,357$ CAN avec les BZD vs 1,180$ pour la 
TCC). La TCC a dominé l’utilisation des BZD avec une économie moyenne de 25, 743$ 
CAN par QALY à cause des chutes moins nombreuses observées avec la TCC. Les 
résultats des analyses d’économies d’argent suggèrent que si la TCC remplaçait le 
traitement par BZD, l’économie annuelle directe pour le traitement de l’insomnie serait 
de 441 millions de dollars CAN avec une économie cumulative de 112 billions de dollars 
canadiens sur une période de cinq ans. D’après le rapport sensibilité, le traitement par 
BZD coûte en moyenne 1,305$ CAN, écart type 598$ (étendue : 245-
2,625)/personne/année alors qu’il en coûte moyenne 1,129$ CAN, écart type 514$ 
(étendue : 342-2,526)/personne/année avec la TCC.  
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Les options actuelles de remboursement de traitements pharmacologiques au lieu des 
traitements non-pharmacologiques pour l’insomnie chez les personnes âgées ne 
permettent pas d’économie de coûts et ne sont pas recommandables éthiquement dans 
une perspective du système de santé.  
Mots clés : benzodiazépines, thérapie cognitive-comportementale, insomnie, population 
âgée vivant en communauté, évaluation économique. 
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Abstract 
Insomnia is common in the geriatric population, typically treated with benzodiazepine 
drugs which can increase the risk of falls. Cognitive behavioral therapy (CBT) is a non-
pharmacological intervention with equivalent efficacy and no adverse events. This thesis 
compares the cost of benzodiazepines versus CBT for the treatment of insomnia in older 
adults, with and without consideration of the additional cost of falls incurred by 
benzodiazepine use. A decision tree model was constructed and run from the health 
payer’s perspective over 1 year.  The probability of falls, ER visits, hospitalisation with 
and without hip fracture, cost data and utilities were derived from a comprehensive 
literature review.  Cost consequence, cost utility and potential cost saving analyses were 
performed. Both probabilistic and deterministic sensitivity analyses were conducted to 
account for uncertainty around the data estimates.  
Benzodiazepine treatment costs 30% less than the price of CBT when the costs of falls 
are not considered (CAN $231 vs. CAN $335 per individual per year).  When the cost of 
falls is considered, CBT emerges as the least expensive option (absolute cost-saving 
CAN$ 177 per person per year, CAN $1,357 with benzodiazepines vs. $1,180 for CBT).  
CBT dominated benzodiazepines, with a mean cost saving of CAN $ 25,743 per QALY 
gained with CBT due to fewer falls. The cost savings analysis shows that if the CBT were 
to completely replace benzodiazepine therapy, the expected annual direct cost savings for 
the treatment of insomnia would be $ 441 million CAD dollars, with a cumulative cost 
savings of $112 billion CAD dollars over 5-years. The PSA report shows that even at 
different varying parameters, benzodiazepines cost CAD$ 1,305, S.D $ 598 (range 245-
2,625) on average / person / year vs. CAD$ 1,129, S.D $ 514 (range 342-2,526) on 
average / person / year for CBT.   
Current treatment reimbursement options that fund pharmacologic therapy instead of 
non-pharmacologic therapy for geriatric insomnia are neither cost-saving nor ethically 
recommendable from the health system’s perspective. 
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Foreword 
Previous economic evaluations assessing the cost-effectiveness of pharmacologic 
treatment for insomnia have not considered the cost and loss of quality of life associated 
with a drug-related increased risk of falls in older adults.  The goal of this Master’s thesis 
was to conduct an economic evaluation of benzodiazepine treatment for geriatric 
insomnia, taking into account the hidden costs associated with an increased risk of drug-
induced falls in the elderly.  The full cost of benzodiazepine treatment compared to 
cognitive behavioural therapy, a non-pharmacologic treatment alternative that exhibits 
equal effectiveness for treating insomnia over the short-term, was assessed.  
This MSc thesis consists of twelve chapters including an introduction, the 
objectives of the study, the methods, the results, discussion, limitations, conclusion and 
future direction.  The introduction provides background on inappropriate prescribing in 
older adults, with benzodiazepines as a prototype medication.  Insomnia, as a prototype 
non-life-threatening chronic disease in the community dwelling elderly is also 
introduced.  
The objectives of the study include the overall as well specific research questions 
of our research project.  The methodology chapter details information about the cost-
minimization, cost-utility analysis and potential cost saving analysis we conducted.  This 
information explains the study design, modelling, and the source of model input 
parameters such as cost and utilities, the target population, and the types of sensitivity 
analyses to check the uncertainty around the different parameters used for the cost utility, 
cost minimization and potential cost saving analysis. 
The results chapters present the findings from the analysis and interpretation of 
the results, as well as the effects of change of the input parameters using a sensitivity 
analysis.  It also projects the effects on government for preferentially reimbursing 
pharmacologic versus non-pharmacologic therapy for insomnia.  The limitations chapter 
reveals several limitations of our analysis, including assumptions for the model.   
xviii 
 
The discussion highlights the strengths of our project, and the contribution of our 
results to the literature in the field of insomnia for the growing elderly population in 
Canada. Finally, we outline further research recommendations for geriatric pharmaco-
economic studies, such as the current analysis on insomnia and falls.  The endnote section 
contains all articles, books, and reports cited in this thesis. 
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Chapter 1. Inappropriate prescribing 
 
 
 
 
 
 
 
 
 
2 
 
1.1. Inappropriate prescribing in older adults 
Much attention has been devoted to the quality of prescribing over the past two 
decades.  The reasons for this are twofold; first, inappropriate prescribing increases the 
occurrence of adverse drug events and second, it incurs a higher risk of drug-drug 
interactions.  So, inappropriate prescribing not only escalates health care costs but also 
impacts the health and quality of life in older adults.  This thesis will focus on 
benzodiazepines as a prototype of inappropriate prescribing in older adults. 
1.2. Definition 
The term potentially inappropriate medication (PIM) refers to medications where 
the associated risks of consumption outweigh the therapeutic benefits (1).  Inappropriate 
prescribing encompasses the use of medications that introduce a significant risk of an 
adverse drug event (ADE) when there exists evidence for an equally or more effective but 
lower-risk alternative therapy for treating the same medical condition (2).  Appropriate 
prescribing is a general phrase encompassing and comprising a range of values and 
behaviors aimed at reflecting the quality of prescribing.  
Many other words are used to describe the quality of prescribing, such as good, 
poor, appropriate or inappropriate, optimal or suboptimal (3).  Additionally some terms 
are specific to some types of inappropriateness- e.g., under-prescribing refers to failure to 
prescribe drugs that are needed, overprescribing refers to prescribing more drugs than are 
clinically needed and mis-prescribing refers to incorrectly prescribing a drug that is 
needed (3).  Three of the most important sets of values in judging appropriateness are 
what the patients want, scientific rationalism (including clinical pharmacology of the 
drugs), and the societal and family- related consequences of prescribing.  A judgement of 
appropriateness will therefore depend on consideration of the facts and circumstances in 
all three domains (3).  However much of the published literature has condensed the 
notion of appropriateness to simple pharmacological appropriateness (4). 
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1.3. The Elderly Population 
The chronological age of 65 is widely accepted to define the elderly or older 
persons in developed countries.  It is recognized that this classification is somewhat 
arbitrary and may not be appropriate in all world populations.  The term ‘elderly’ in fact 
describes a heterogeneous population in terms of constitution, health and functional 
performance, quality of life, and life expectancy. 
Older adults represent a large segment of the Canadian population.  In 2010, an 
estimated 4.8 million Canadian were 65 years of age or older, a number that is expected 
to double in the next 25 years to reach 10.4 million seniors by 2036.  By 2051, about one 
in four Canadians is expected to be 65 years of age or over (5). 
Medication is a fundamental component of the health care of older adults.  
Heterogeneity within the older population renders the selection of appropriate 
pharmacotherapy for each individual more difficult.  Some older adults will be more fit 
and others vulnerable and frail.  Variations in health status often lead to altered 
pharmacokinetic and enhanced pharmacodynamic sensitivity to specific drugs.  A higher 
prevalence of geriatric syndromes such as cognitive impairment and dementia may also 
impede older adults’ ability to make autonomous decisions and correctly adhere to drug 
dosing schedules (3). 
1.4. Measure of appropriateness in older adults 
Inappropriate prescribing in older adults can be assessed by explicit criteria or 
implicit criteria.  Explicit criteria are criterion based and are usually developed from 
published literature, expert opinions, or consensus techniques (6).  Expert opinion is 
usually needed in geriatric medicine because evidence-based aspects of treatments are 
frequently absent.  Explicit measures are drug-oriented or disease-oriented, alternatively 
termed “lists of drugs to avoid”, and can be applied with little or no clinical judgment.  
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1.4.1. Explicit criteria 
Researchers in the United States were early developers of criteria to evaluate 
inappropriate prescribing in older adults; the first criteria were developed in the early 
1990s by Beers et al. and revised thrice in the year 1997, 2003 and 2012 (1, 7, 8) ( Table 
1).  In Europe, the first consensus-validated criteria were developed in France more than 
a decade later by Laroche et al. in 2007 (9) followed by Gallagher et al. in 2008 (10) in 
Ireland.  Of the criteria resulting from the literature search (n=8), four (50%) were 
developed in the Europe (9-12), two (25%) in Canada(13, 14), and one (12%) in the 
United States(8) and Thailand (15). 
Table 1 Explicit Criteria 
 McLeod Beers (Modified) Rancourt Laroche STOPP 
Winit-
Watjana NORGEP 
PRISCUSS 
 LIST 
Updated 
Beers 
Criteria 
Year of 
publicatio
n 
1997 2003 2004 2007 2008 2008 2009 2010 2012 
Country Canada United States Canada France Ireland Thailand Norway Germany 
United 
States 
Number 
of 
statements 
38 68 111 34 65 77 36 131 68 
No. of 
experts 
(no. of 
Delphi 
rounds) 
32 (2) 12 (2) 4 (2) 15 (2) 18 (2) 17 (3) 47 (3) 26 (2) 11 (2) 
Applicabl
e age 
groups 
(years) 
≥ 65 ≥ 65 ≥ 65 ≥ 75 ≥ 65 
Not 
Specified 
(Older) 
≥ 70 ≥ 65 ≥ 65 
Long-
acting 
benzodiaz
epines 
listed as 
                  
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PIMs 
Tricyclic 
antidepres
sant listed 
as PIMs 
                  
 
Although the number of experts in Delphi rounds differ and range from 4 (14) to 
47 (11) but contents of all the eight criteria (8-15) have been validated in two or three 
rounds of  Delphi technique.  The Norwegian General Practice (NORGEP) criteria (11) 
was designed for persons aged 70 and older and the French criteria (9) for people aged 75 
and older.  No specific age was mentioned in the criteria developed in Thailand (15) 
while all remaining (8,10,12,13,14) were designed for persons aged 65 and older.  
The Beers 1991 criteria (7) were generated for a vulnerable subgroup of 
individuals aged 65 and older.  Most criteria were applied to non-hospitalized people 
aged 65 years and older.  All the explicit criteria (8-15) include long-acting 
benzodiazepines and tricyclic antidepressant as potential inappropriate medication in 
older adults.  The expert panels were composed of gerontologists and physicians whose 
practices concentrate on older adults.  
In 2012, a panel of 11 experts updated the beers criteria.  The 2012 Beers Criteria 
is an important and improved update of previously established criteria widely used by 
healthcare providers, educators, and policy-makers and as a quality measure.  In earlier 
beers criteria, as many as 40% of older adults received one or more medications on this 
list, were depending on the care setting.   
The new criteria are based upon methods for determining best-practice guidelines 
that included a rigorous systematic literature review, the use of an expert consensus 
panel, and grading of the strength of evidence and recommendations.  This criterion 
recommends avoiding benzodiazepines in older adults for the treatment of insomnia.  The 
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drug selection has been modified according to the developing country's drug selection.  
The association with the Beers criteria (1, 7, 8) can also be an advantage.  
 It means that these criteria comprise certain basic items that have been proven 
valid through many consensus panels and offer, to some extent, transnational 
comparability of the process.  United States researchers lead by being the only ones who 
have been updating their criteria (1, 8) and by publishing a new set of explicit criteria for 
determining preferred (rather than potentially inappropriate) medications for individuals 
aged 65 and older in 2009 (16).  Explicit criteria cannot capture the clinical details of the 
patient accurately; hence do not take into account all factors that define high quality 
health care for the individual.   
For example in the Assessing Care of Vulnerable Elders Project (ACOVE) 
proposes quality-of-care markers for chronic diseases and geriatric syndromes in frail 
older adults and recognizes that the goals of care and preferences affect definitions of 
quality. Patient-reported measures of quality of care address access, continuity, 
coordination, communication, and empowerment for patient and family involvement 
(17).  They generally do not address the burden of comorbid disease and patients' 
preferences(18). Additionally, consensus approaches have little evidence of validity or 
reliability (19). 
1.4.2. Implicit criteria 
In implicit approaches, a clinician or clinical pharmacist uses information from 
the patient’s chart and scientific evidence on outcomes to make judgments about 
appropriateness.  The focus is usually on the patient rather than on drugs or diseases. 
These approaches are potentially the most sensitive and can account for patients' 
preferences, but they are time-consuming, depend on the user's knowledge and attitudes, 
and can have low reliability (3). 
Reliability can be improved with detailed specifications, instrument to obtain 
data, and by training data collectors (20), as done with the Medication Appropriateness 
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Index (MAI) (21).  Some of the criteria are developed in randomized controlled trials of 
individuals aged 65 and older, their validity has been demonstrated using medical records 
of the participants in these trials (22, 23).  The Assessment of Underutilization of 
medication (AOU) has been validated in a small case study in a long-term care facility 
(24). 
Existing measures of medication inappropriateness using implicit criteria include 
pharmacological appropriateness of prescribed drugs (23, 25, 26).  Although much of the 
published work on medication inappropriateness has been conducted using explicit 
process measures, there is no ideal measure.  Rather, the strengths and weaknesses of 
both approaches should be considered (3). 
1.5. Prevalence of potentially inappropriate medications in older 
adults 
The prevalence of potentially inappropriate medications in older adults is 
provided in Table 2. Recent data indicate that the majority of older persons takes at least 
one prescribed drug, with more than one-third of patients taking four drugs or more (27).   
The following review of the literature indicates that the use of medicines in elderly 
people is often inappropriate.  One of the first reports of inappropriate prescribing in the 
elderly, more than 20 years ago, quoted that one quarter of older patients admitted to the 
general medical and geriatric beds of a teaching hospital were prescribed a 
contraindicated or adversely interacting drug, and that at least 65.5% of adverse drug 
reactions could have been avoided (28). 
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Table 2 Prevalence of potentially inappropriate medications in older adults 
Author, year Country, 
setting 
Sample size Study design, 
population 
PIM 
Criteria 
Prévalence/incidence of 
PIM 
% of BZP (overall/ Outcome, 
 Yes/No 
Wilcox et al. 
1994 
United States, 
American 
aged 65 years 
or older living 
in the 
community 
6171 
people 
Cross-sectional 
survey, 
Community 
dwelling 65 
years or older 
Beers 
criteria 
18.7 % received at least 
one PIM while 4.8% 
received two or more PIM 
Diazepam-2.8 %, 
Chlordiazepoxide-1.95, 
Flurazepam-1.25% 
No 
Chin et al. 
1999 
United States, 
65 years or 
older 
admitted to an 
urban hospital 
ED 
898 
Patients 
aged 65 and 
older 
Prospective 
cohort study, 
All eligible 
patients (65 
years or older) 
presented to the 
ED 
Revised 
Beers 
criteria 
(1997) 
10.6 % taking PIM, 
3.6%were given in the ED 
while 5.6% received upon 
discharge 
9%  prescription for 
benzodiazepines received 
as a PIM 
Yes, Adverse drug-
disease interactions 
Golden et al. 1999 United States, 
Nursing home 
eligible, home 
bound older 
population 
2193 aged 
60 and over 
Retrospective 
cross-sectional, 
Nursing-home 
eligible home 
bound elderly 
Revised 
Beers 
criteria 
(1997) 
39.7% taking at least one 
while 10.4% had two or 
more 
41.6% overall 
benzodiazepine prevalence 
while 7.6 % prescribed 
more than one  
No 
Hanlon et al. 2000 United States, 
Community 
dwelling 
elderly in 
North 
Carolina 
3314 
patients in 
wave 2; 
2551 
patients in 
wave 3 
Retrospective 
cross-
sectional/2nd 
and 3rd wave 
Duke 
established 
population  
Revised 
Beers 
criteria 
(1997) 
27% of all participants in 
wave 2; 22.6% in wave 3 
NA No 
Mort et al. 2000  United States,  
Ambulatory 
visit and 
hospital OPD 
(Psychotropic  
medications 
only) 
1,373 
patients 
Retrospective 
cross-sectional 
/Office based 
and out-patient 
setting 
Revised 
Beers 
criteria 
(1997) 
27.2 %  had at least one 
PIM 
Flurazepam 1.2%, 
Diazepam 7.43%, 
Chlordiazepoxide 2.51% 
No 
Mott et al. 
2000 
United States, 
Elderly with 
Rx. Filled at 
community 
pharmacies 
1530 new 
Rx. For 
1185 aged 
65 and 
older 
Retrospective 
cross-
sectional/Comm
unity 
pharmacies 
Beers 
Criteria 
14.3 % had at least one 
PIM 
NA No  
Zhan et al. 2001 United States, 
Community 
dwelling 
elderly 
2455 aged 
65 and 
older 
Retrospective 
cross-sectional/ 
community 
dwelling elderly 
Explicit 
Criteria 
21.3 % had at least one 
PIM 
NA No 
Hanlon et al. 2002 United States, 
Community 
dwelling 
elderly in 
North 
Carolina 
3234 
patients at 
4th 
interview; 
2451 
patients at 7 
Retrospective 
cross-
sectional/Duke 
established 
population 
Beers 
modified 
criteria 
28%  of all the patients NA Yes, mortality and 
functional status 
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Author, year Country, 
setting 
Sample size Study design, 
population 
PIM 
Criteria 
Prévalence/incidence of 
PIM 
% of BZP (overall/ Outcome, 
 Yes/No 
Moride et al.* 2002 Canada, 
Community 
dwelling 
elderly 
persons 
3400 
persons 
aged 65 and 
older 
Cross-sectional 
self-reported 
survey 
Beers 
criteria, 
implicit by 
Quebec 
drug 
insurance 
plan 
6.5 % used more than one 
PIM 
8.5 % Reported using 2 
concomitant BZP while 4.2 
% reported using more 
than 1 long acting BZP. 
Yes, drug-drug 
interactions 
Pitkala et al. 2002 Finland, 
Elderly urban 
residents aged 
75,80,85,90 
and 95 years 
3921 
persons 
Cross-sectional 
study, home-
dwelling older 
persons 
Revised 
Beers 
criteria 
(1997) 
12.5% at least 1, 1.3% 
taking 2, while 0.3% 3 
PIM 
Long-acting BZP 2.6% No 
Stuart et al. 2003 United States, 
Community 
dwelling 
elder person  
7628  
persons 
from the 
1995 
MCBS and 
8902 from 
1999 
MCBS 
Retrospective 
cross-sectional 
study / 
Medicare 
current 
beneficiary 
from the year 
1995 and 1999. 
Revised 
Beers 
criteria 
(1997) 
24. 8% taking >1 PIM in 
1995 while 21.3 % in the 
year 1999. 
Diazepam 1.9% - 1.5%, 
Chlordiazepoxide 0.6% - 
0.5%, Flurazepam 0.6% - 
0.2% 
No 
Howard et al. 2004 Canada, 
Senior 
patients 
selected from 
randomly 
selected 
family 
practices 
777 
patients 
Randomized 
trials, 
Community 
dwelling 
patients 
Beers 
modified 
criteria 
16.3% had at least one PIM 6.4% (Short-acting BZP), 
most common category of 
PIM  
No 
 
Cornelis et al. 2004 Netherland, 
all patients 65 
and over from 
150 general 
practitioners 
18030, 
20947, 
29605, 
26378 and 
25258 
persons 
from 1997-
2001. 
Prospective 
cohort study, 
Ambulatory 
older adults 
Beers 
criteria and 
Beers 
modified 
criteria 
16.8% to 18.5% for at least 
one PIM (1997), 19.1% to 
20 % (Modified Criteria) 
Diazepam 2.8%, 
Flurazepam 0.5%, 
temazepam 2% (Highest 
Rx. Supratherapeutic dose) 
and chlordiazepoxide 
(0.2%) in 2001. 
Yes, relation of PIM 
to co-morbidity 
Michel et al. 2004 France, 
Three-city 
study, a 
French 
longitudinal 
study 
9294 
patients 
Observational 
Longitudinal 
Study, 
Community 
dwelling 65 
year and older 
population 
Beers 
criteria 
modified 
by a panel 
of French 
experts 
Nearly 40 % used at least 1 
PIM 
9.2 % long acting BZP (3rd 
highest) Bromazepam 
(4.9%) was the most often 
reported 
No 
Azoulat et al. 2005 Iran, Out-
patient visits 
3000 
patients 
Cross-sectional 
study, 
community 
dwelling patient 
65 years or 
older 
Revised 
Beers 
criteria 
(1997) 
27.6% had at least one PIM BZP overall (16%), 
Chlordiazepoxide 7.2% 
while diazepam 5.3% 
No 
Moral et al. 2006 Spain, 14 
rural primary 
care centers 
143 
patients 
Cross-sectional 
descriptive 
study, Immobile  
Beers 
modified 
criteria 
Nearly 35 % used at least 1 
PIM 
Not given No 
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Author, year Country, 
setting 
Sample size Study design, 
population 
PIM 
Criteria 
Prévalence/incidence of 
PIM 
% of BZP (overall/ Outcome, 
 Yes/No 
Maio et al. 2006 Italy, 
Outpatient 
Rx. Claim 
data base 
849 425 
patients 
Retrospective 
cohort study, 
outpatient aged 
65 years or 
older 
Beers 
modified 
criteria 
18% used at least 1 PIM, 
while 11.5% received in 2 
and 1.7% for 3 and more 
PIM 
Not given (Bcz not studied 
as BZP are not reimbursed 
by INF) 
No 
Gallagher et al. 
2008 
Ireland, Old 
Patients 
admitted to a 
university 
teaching 
hospital 
597 
consecutive 
acute 
admissions 
Prospective 
observational 
studies, non-
selected 
community 
dwelling 
population 
requiring 
hospitalization 
Beers 
modified 
criteria 
24% taking 1, 6% taking 2 
and 2% taking more than 2 
PIM 
Over 50% of all PIM were 
for psychotropic 
medications, with over 
80% of this subgroup being 
for BZP. 
No 
Wessell et al. 2008 United states, 
99 primary 
care practices 
124,802 
active 
patients 
Prospective 
demonstrative 
project, primary 
care patients 65 
years or older 
Beers 
modified 
criteria 
Decreased from always 
inappropriate 0.41% to 
0.33 %, Rarely appropriate 
1.48 to 1.30%  
Always inappropriate- 
Flurazepam while Rarely 
appropriate diazepam and 
chlordiazepoxide 
No 
Stafford et al. 2009 Australia, 
Care home 
residents 
2345 
residents 
Retrospective 
cohort study, 
Patient residing 
in care homes 
65 years or 
older 
Beers 
modified 
and Mc 
leod 
Criteria 
43.8% at least 1 PIM, 
Beers criteria (35.3%) 
identified more PIM than 
McLeod (18.7%) 
Beers (Temazepam 13.9%, 
Oxazepam 7.2%, 
Diazepam 5. %, 
alprazolam 2.2%) McLeod 
(Diazepam 7.1% in 
dementia and 6.4 % in 
anxiety) 
No 
Berdot et al. France, 
Three-city 
study, a 
French 
longitudinal 
study 
6343 
participants 
Prospective 
cohort study, 
Community 
dwelling 65 
years or older 
Beers 
modified 
criteria 
32 %  7.8% Long-term BZP 
while 12.2% short or 
intermediate acting BZP 
Yes, Association 
with falls 
Zaveri et al. 2010 India, 
Medicine 
OPD at a 
tertiary care 
hospital 
407 
geriatric 
patients 
Prospective 
cross-sectional 
study, 
Ambulatory 
patients 65 
years or older 
Beers 
modified 
criteria 
23.58% Diazepam 2.8%, Higher 
dose of Lorazepam and 
alprazolam 
No 
Ruggiero et al. 
2010 
Italy, 
ULLISE 
Project 
1716 long 
term 
resident 
Prospective 
cross-sectional, 
nursing home 
residents 65 
years or older 
Beers 
modified 
criteria 
48% at least 1, 11.7% two 
while 6.1 % had 3 or more 
PIM 
Long acting BZP 3.7 %, 
short acting BZP 0.8% 
Yes, Risk of 
hospitalization 
Barnett et al. 2010 Scotland, 
Residence of 
Tayside, 
Scotland 
70299 
patients  
Cohort study 
stratified by 
residence 
All people 
between 65 and 
99 years 
Beers 
modified 
criteria 
At home, 23.2% at least 1, 
6% 2 while 1.7% received 
3 or more PIM, at care, 
27.1%, 1, 8% ,2 and 2% 
received 3 or more PIM 
Long acting BZP, at home, 
6.36% while at care 11.13 
%            were the third 
most commonly Rx. PIM       
Yes, Increased risk 
of death 
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Author, year Country, 
setting 
Sample size Study design, 
population 
PIM 
Criteria 
Prévalence/incidence of 
PIM 
% of BZP (overall/ Outcome, 
 Yes/No 
Sakuma et al. 2011 Japan, Three 
acute care 
hospitals 
2155 
elderly 
patients 
Prospective 
cohort study,   
Patients aged 65 
years or older 
Beers 
modified 
criteria 
56.1% received at least one 
PIM 
Diazepam 9.5% Yes, drug related 
adverse events 
Bongue et al. 2011 France, EGB 
data bases 
35,259 
patients  
Retrospective 
cross-sectional 
study, patients 
aged 75 and 
older 
Explicit 
criteria/ 
French PIM 
List 
53.6 % received at least 1 
PIM 
Long acting BZP 17.8 %  
 
More recent data indicate that the prevalence of potentially inappropriate 
medications in community dwelling older adults ranges from 12.5% (29) to 43.8% (30) 
receiving at least one potentially inappropriate drug, and in nursing home residents from 
16.8% (31) to 56.1% (32).  The criteria that are used to assess potentially inappropriate 
medications have an effect on the prevalence of use of these drugs.  Differences in 
prevalence can therefore be partially explained by the criteria used.  For example a study 
conducted in 2009 (30) (Australia) compared the modified beers criteria with McLeod’s 
criteria for assessing prescribing appropriateness in patients residing in care homes and 
found a prevalence of inappropriate medications in 35.3% of patients using the  modified 
beers criteria compared to half the rate (18.7%) using McLeod’s criteria.  Similar results 
have been reported in Ireland where a higher prevalence of inappropriate prescribing was 
obtained using the STOPP criteria than by using Beers criteria in both the community 
(21% vs. 18%) and the hospital setting (35% vs. 25%) (33). 
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Chapter 2. Benzodiazepines as a prototype of 
inappropriate prescribing in older adults 
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2.1. Introduction 
Long acting benzodiazepines are among the most frequently reported 
inappropriate prescriptions in older adults (Table 2).  These medications are considered 
inappropriate by all eight existing explicit criteria (Table 1).  The tricyclic antidepressants 
are the only other potentially inappropriate medication reported by all criteria. 
Benzodiazepines are psychoactive drugs whose core chemical structure is the fusion of a 
benzene ring and a diazepine ring, which enhances the effect of the neurotransmitter 
gamma-amino butyric acid (GABA), resulting in sedative, hypnotic (sleep-inducing), 
anxiolytic (anti-anxiety), anticonvulsant, muscle relaxant and amnesic action (34).  These 
properties make benzodiazepines useful for treating anxiety, insomnia, agitation, 
seizures, muscle spasms, alcohol withdrawal and as a premedication for medical or dental 
procedures in older adults.  
2.2. Classifications of benzodiazepines 
Benzodiazepines are classified as short acting, intermediate acting or long acting, 
depending on their elimination half-life (35).  (Table 3) 
Table 3 Classification of benzodiazepines 
Short acting Common Brand Name Elimination Half-Life 
Alprazolam Xanax 6-12 hours 
Bromazepam Lexotan, Lexomil 10-20 Hours 
Brotizolam Dormex 4-5 hours 
Chlordiazepoxide Librium 5-30 hours 
Cinolazepam Gerodorm 9 hours 
Estazolam Prosom 10-24 hours 
Etizolam Etilaam 6 hours 
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Loprazolam Dormonoct 6-12 hours 
Lorazepam Ativan 10-20 hours 
Lormetazepam Loramet 10-12 hours 
Midazolam Dormicum 3 hours 
Oxazepam Serax 4-15 hours 
Temazepam Restoril 8-22 hours 
Tetrazepam Mylostan 3-26 hours 
Triazolam Rilamir 2 hours 
Intermediate acting Common Brand Name Elimination Half-Life 
Clonzepam Rivotril 18-50 hours 
Cloxazolam Sepazon 18-50 hours 
Chlorazepate Tranxene 36-100 hours 
Diazepam Valium 20-100 hours 
Flunitrazepam Flunipam 18-26 hours 
Halazepam Paxipam 30-100 hours 
Ketazoalm Anxon 30-100 hours 
Nimetazepam Erimin 14-30 hours 
Nitrazepam Mogadon 15-38 hours 
Long  acting Common Brand Name Elimination Half-Life 
Phenazepam Phenazepam 60 hours 
Pinazepam Domar 40-100 hours 
Prazepam Centrax 36-200 hours 
Quzepam Doral 39-120 hours 
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Nordazepam Madar 50-120 hours 
Medazepam Nobrium 36-200 hours 
Flutoprazepam Restas 60-90 hours 
Flurazepam Dalmane 40-250 hours 
1. Short-acting compounds have a median half-life of 1–12 hours.  They have few 
residual effects if taken before bedtime.  Rebound insomnia may occur upon 
discontinuation, and they might cause daytime withdrawal symptoms such as next 
day rebound anxiety with prolonged usage. 
2. Intermediate-acting compounds have a median half-life of 12–40 hours.  They 
may have some residual effects in the first half of the day if used as a hypnotic. 
Rebound insomnia, however, is more common upon discontinuation of 
intermediate-acting benzodiazepines than longer-acting benzodiazepines.  
3. Long-acting compounds have a half-life of 40–250 hours.  They have a risk of 
accumulation in the elderly and in individuals with severely impaired liver 
function, but they have a reduced severity of rebound effects and withdrawal.  
2.3. Indications and adverse events due to benzodiazepine use 
Clinicians in general tend to use long half-life benzodiazepines in patients, who 
have difficulties maintaining sleep and short half-life benzodiazepines for treating sleep 
onset insomnia.  Short and long half- life benzodiazepines are used for both indications 
and most clinicians feel that the choice of hypnotic should not only be influenced by 
elimination half-life or the dosage used, but by individual patient preference (36).  The 
most frequent indications for benzodiazepine, according to an analysis of patterns of use 
in 2262 persons were anxiety (1/3), insomnia (1/3), or crisis (1/4) (37). 
In general, benzodiazepines may be safe and effective in the short term, although 
cognitive impairments and paradoxical effects such as aggression or behavioural 
disinhibition occasionally occur ((38).  Long-term use is controversial due to concerns 
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about adverse psychological and physical effects, diminished effectiveness and because 
benzodiazepines are prone to cause tolerance, physical dependence, and, upon cessation 
of use, a withdrawal syndrome (39).  Due to adverse effects associated with the long-term 
use of benzodiazepines, withdrawal from benzodiazepines, in general, leads to improved 
physical and mental health (40).  A list of adverse events associated with the use of 
benzodiazepines is provided in Table 4. 
Table 4 List of adverse events related to use of benzodiazepines 
Adverse 
Events 
References Type of study ODDs Ratio (OR) 
in  18-65 years 
adults 
 ODDs Ratio (OR) in  65+ years 
older adults 
Falls 
 
Bloch et al. 
2011 
 
Systematic 
literature review 
and meta-analysis 
Not reported 
 
1.39 (1.24-1.54) For Institutional 
1.61(1.35-1.93) For Ambulatory 
1.27(1.11-1.46) 
 Woolcott et al. 
2009 
 
Cohort, case-
control cross-
sectional studies 
Not reported 
 
1.57 (1.43-1.72) 
 
 Lavasa et al. 
2010 
Case-control 
 
Not reported 2.49 (1.98-3.14) 
 
 Francesco et 
al. 2005 
Observational 
Study 
 
Not-reported 
1.45 (1.00-2.11) for long half life 
1.32 (1.02-1.72) for short half life 
 Stenbacka et 
al. 2002  
Cohort Not-reported 
 
For women’s 
1.34 (1.09-1.63) once 
1.51-(1.14-2.01) Frequent falls 
 Frels et al. 
2002 
Case control 
 
Not reported 
 
2.3 (1.4-3.7) 
 Ray et al.2000 Cohort  Not reported 1.44 (1.33-1.56) RR 
 Leipzig et al. 
1999 
 
Systematic review 
and meta-analysis 
Not reported 
 
1.48 (1.23-1.77) for all 
1.44 (1.09-1.90) short 
1.32 (.98-1.77) long 
 Berdot et al. 
2009  
 
Prospective cohort 
 
Not reported 
 
1.58 (1.26-1.98) long acting, 
occasional user 
1.65 (1.33-204)regular 
1.34(1.10-1.63) short acting, 
occasional 
1.32(1.08-1.60)regular 
 Chang et al. 
2010 
Case-control 
 
Not reported 
 
2.26 (1.21-4.23) 
 
Fractures 
 
Takkouche et 
al. 2007  
Meta-analysis 
 
Not reported 
 
RR 1.60 (1.38-1.86) 
17 
 
 Ensrud et al. 
2003  
Cohort Not reported 1.28(1.05-1.57) HRatio, nonspine 
frac. 1.54(1.04-2.28) hip farcture 
 Sebastian et al 
2005 
Cross-sectional Not reported 1.38(1.14-1.66) After correcting 
confounding Potential cost saving 
analysis in data claims 
 Chang et al. 
2007  
 
Nested case-control 
 
Not reported 1.7 (1.2-2.5) 
1.8(1.1-3.1) >3mg/day of diazepam 
equivalent 1.8(1.3-2.7) short-acting 
 Bolton et al 
2008 
population based 
analysis 
50+ 
1.10(1.04-1.16) 
Not reported 
 Finkle et al. 
2011 
Cohort study Not reported 1.14(0.80-1.64) Alprazolam 
1.53(1.23-1.91) lorazepam 
Motor-
vehicle 
accidents 
Hemmalgarn 
et al. 1997 
 
Nested case-control 
 
Not-reported RR 1.45(1.04-2.03) 1ST Week 
1.04(0.81-1.34) after treatment 
initiation with short acting 
 Orriols et al. 
2011 
Cohort study 
 
1.39 (1.08-1.79) 0.47 % 
Cognitive 
impairment 
Paterniti et al. 
2002 
Longitudinal study Not-reported 1.9 (1.0–3.6) 
 Cazou et al. 
2011 
Cohort study (β=−2.13±0.67, 
p<0.01) in delayed 
free recall  
Not reported 
 
Benzodiazepines produce instantaneous effects, and thus may be prescribed for 
short-term, intermittent, or "as-needed" use. Because many anxiety disorders wax and 
wane over time, patients with these disorders prefer benzodiazepines because these 
agents can be taken intermittently, when patients feel the need to take them (41).  Older 
adults are avid consumers of benzodiazepine medication.  
In Canada, the use of long half-life benzodiazepines in 2001 was 20.0% in those 
aged 65 and over (42).  The proportion of benzodiazepine prescriptions was the highest 
among all psychotropic medications in 2002 (43).  According to the national population 
health survey; clonazepam (14.8%) and lorazepam (38.3%) were the highest prescribed 
benzodiazepines in 2002 (42). 
Overall prescriptions of benzodiazepine have decreased consistently over time 
(25.1% in 1993 to 22.5% in 1998; P < .001).  However, the prevalence of benzodiazepine 
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dispensing increases with increasing age (approximately 20% of those age 65 to 69 to 
approximately 30% of those ages > or =85; P < .001) (44).  Benzodiazepines have been 
associated with several adverse effects, including ataxia, dizziness, over-sedation, 
anterograde amnesia, and dependence (45).  Recently a prospective cohort study 
conducted by Gillian Bartlett et.al concluded that benzodiazepines are commonly used 
medicinally among elderly persons, even among those with pre-existing conditions that 
strongly increase their risk of injuries from falls (46). 
The elderly are at an increased risk of suffering from both short- and long-term 
adverse effects of benzodiazepines (47).  The severity of adverse effects, particularly 
those associated with the central nervous system, may be greater in older adults (8, 48).  
The association between benzodiazepine use and relatively infrequent but clinically 
important side effects such as falls, fractures, cognitive impairment and motor vehicle 
accidents is well established.  
A number of observational studies have demonstrated an association between 
benzodiazepines and adverse events in the elderly, such as falls, hip fracture, cognitive 
impairment, and auto accidents (49-58).  A recent critical systematic review on 
medications as a risk factor for falls includes 29 studies out of which twenty-seven 
studies reported results using CNS drugs, and all of them included at least one 
psychotropic drug or drug group.  Benzodiazepines as a group or by certain preparations 
were associated with falls or fall-related fractures in 17 studies.  
The risk of falling increases after a new prescription, in long-term use and 
regardless of the preparation's half-life.  Concomitant use of two or more 
benzodiazepines increased the risk of hip fracture 2-fold. In contrast, three studies found 
no association between the use of benzodiazepines and falls (59).  A recent cohort study 
conducted in Quebec showed that patients with pre-existing conditions that increase the 
risk of injurious falls are significantly more likely to receive a new prescription for a 
benzodiazepine, further increasing the chances of injurious falls (45). 
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Two meta-analyses conducted on the association between benzodiazepine use and 
risk of falling in older adults (60, 61) using different studies showed an odds ratio of 1.57 
(95% CI, 1.43-1.72) and 1.39 (95% CI, 1.24-1.54) for benzodiazepine use and risk of 
falls.  Woolcott et al (60) used Bayesian methodology by incorporating the results of 
previous meta-analysis conducted by Leipzig et al. (62) while Bloch F et al. (61) included 
all studies apart from studies included by Woolcott et al. (60).  They defined their 
methodological quality criteria to reduce heterogeneity, publication and selection bias to 
increase the reliability of the meta- analysis.   
Cornellis et al. (63) conducted a nested case–control study in a population-based 
cohort of 7983 older adults and demonstrated that the association between inappropriate 
benzodiazepine use and risk of fractures was also statistically significant (OR 1.80, 95% 
CI 1.16, 2.78). Cornellis et al. compared the effect of use of long vs. short-acting 
benzodiazepines, and found no statistically significant difference in the risk of fracture 
(OR 1.23, 95% CI 0.73, 2.08).  However, when assessing the duration of use, people 
using between 14 and 90 days had a significantly higher risk of fracture than those using 
≤14 days (OR 2.15, 95% CI 1.14, 4.08).   
A recent meta-analysis conducted by Takkouche B et al. (64)  included 23 cohort 
and case-control studies published between 1987 and 2005, and revealed a random 
effects relative risk  of 1.34 (95% CI 1.24-1.45) for fractures in benzodiazepine users.  
There was no evidence of a substantial difference in pooled relative risk according to 
study design (case-control vs. cohort), type of control (population-based vs. hospital-
based) or duration of action (long-term vs. short-term benzodiazepine therapy).  In a 
systematic literature review conducted by Thomas (65) using case control studies from 
five provinces in Canada and the United States showed an odds ratio range from 0.90 to 
6.5 for the association between benzodiazepines and fracture.  Three studies conducted in 
Quebec, Seattle and Tennessee included participants aged 65 and older while others were 
for 18 and older.   
20 
 
In police and emergency ward studies, BZD use was a factor in 1% to 65% of 
accidents (65).  In another study, where subjects had blood alcohol concentrations less 
than the legal limit, benzodiazepines were found in 43% and 65% of subjects (66).  In a 
recent systematic review and meta-analysis(67) of 21 epidemiological studies (13 case 
control and 8 cohort studies), benzodiazepines were associated with a 60% (for case-
control studies: pooled odds ratio 1.59; 95% CI 1.10, 2.31) to 80% (for cohort studies: 
pooled incidence rate ratio 1.81; 95% CI 1.35, 2.43) increase in the risk of traffic 
accidents and a 40% (pooled OR 1.41; 95% CI 1.03, 1.94) increase in 'accident 
responsibility'.  
Co-ingestion of benzodiazepines and alcohol was associated with a 7.7-fold 
increase in the accident risk (pooled OR 7.69; 95% CI 4.33, 13.65).  In a literature review 
for 6 studies, two studies reported a lower risk of cognitive decline in former or ever 
users, two found no association whatever the category of user, and three found an 
increased risk of cognitive decline in benzodiazepine users (68).  A meta- analysis 
conducted by Melinda J et al. (69) conducted on 10 studies with the age range of 21-75, 
showed a mean weighted effect size of 0.41 (median=0.37) with a standard deviation of 
0.22 for persistence of cognitive effects after withdrawing benzodiazepines. 
2.4. A focus on falls 
Falls are the second leading cause, after motor vehicle collisions, of injury-related 
hospitalizations for all ages, accounting for 29% of injury admissions (70).  Falls are the 
leading cause of injury hospitalizations for seniors across the country, contributing to 9% 
of all emergency department visits by seniors and almost 62% of injury-related 
hospitalizations for seniors are the result of falls (71).  Falls can lead to serious injuries, 
reduced mobility, nursing home admission and death (72).  
The fall-related injury rate is nine times greater among seniors than among those 
less than 65 years of age (73).  Almost half of seniors who fall experience a minor injury, 
and 5% to 25% sustain a serious injury such as a fracture or a sprain (74, 75).  It is 
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estimated that about 0.2 to 1.5 per cent of falls result in a hip fracture, which in terms of 
morbidity and mortality is one of the most serious consequences of a fall (76).  
Falls are also the most common cause of traumatic brain injuries, accounting for 
46 per cent of fatal falls among older adults (77).  A systematic review of international 
studies (78) showed that fall-related costs ranged between 0.85 per cent to 1.5 per cent of 
the total health care expenditure of countries such as North America, Australia, Europe, 
and the United Kingdom, equating to 0.07 per cent to 0.20 per cent of the Gross 
Domestic Product.  For comparison purposes, costs were expressed in terms of U.S. 
dollar (USD) purchasing power parities (PPPs). 
In a recent study conducted in Ontario (Canada), average costs for seriously 
injured fallers and non-faller controls were CAD$ 44,203 and CAD$ 13,507, while 
length of stay was 45 and 11 days respectively.  Hospital costs for a seriously injured 
faller were $30,696 (95% CI: $25,158 - $36,781) greater than the cost for a non-faller 
(79).  In a study conducted in the United States, the authors reported that falls cause more 
than 90% of all hip fractures in seniors and 20% die within a year of the fracture in the 
United States (80).  
Families are often unable to provide care, and 40% of all nursing home 
admissions occur as a result of falls by older people (81).  Even without an injury, a fall 
can cause a loss in confidence and a curtailment of activities, which can lead to a decline 
in health and function and contribute to future falls with more serious outcomes (82).  
The magnitude of the problem of falls among older adults is reflected in the 300% 
increase in publications on the issue between 1985 and 2005 (83).  A 20% reduction in 
falls would translate to an estimated 7,500 fewer hospitalizations and 1,800 fewer 
permanently disabled seniors.  The overall national savings could amount to $138 million 
annually (84). 
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2.5. Prevalence of benzodiazepine use in Canada 
According to the Canadian Institute for Health Information, 2008 (National 
prescription drug utilization information system databases), temazepam was the one of 
the top five medications used by seniors on a chronic basis (85).  Benzodiazepines are 
widely prescribed, with two of them, ativan and apo-lorazepam, listed among the top 13th 
and 18th most commonly prescribed medications to the general population.  Clonazepam 
was among the top 10 prescribed medications by psychiatry specialists in Canada in 
2010.  The prevalence of benzodiazepine use among Canadian seniors (those aged 65 
years and older) varies. The overall prevalence of benzodiazepine usage in geriatric 
population is provided in Table 5. 
Table 5 Prevalence of benzodiazepine  
Author, year Country, setting Sample size Study Design, 
population 
% of BZP (overall/ specific)  Outcome, 
Yes/No 
Ineke N. C et al. 2012 Norway, Norwegian 
Prescription Database 
200,000 Retrospective Cohort 
study, patients 70 
years of age and older 
Anxiolytics 15.6% while hypnotics it was 
3.6% 
No 
Fortin et al*. 2011 Canada, Quebec Health 
survey 
1,701 persons Cross-sectional study, 
adults 66 years and 
older 
26.2 %  women reported using BZP while 
the men were 16 % 
No 
Beland et al.* 2011 Canada,  Quebec survey on 
seniors health 
2,798 persons Cross-sectional study, 
adults 65 years and 
older 
25.2 %  reported using BZP Yes, quality of 
sleep 
Voyer et al.* 2010 Canada,  Quebec survey on 
the health of older persons 
2,785 persons Descriptive Study, 
adults 65 years of age 
and older 
25.4 %  reported using BZP, Lorazepam 
(42.3 %) and Oxazepam (21.3%) were the 
highest  
Yes, 
Dependence 
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Author, year Country, setting Sample size Study Design, 
population 
% of BZP (overall/ specific)  Outcome, 
Yes/No 
Smith et al. 2008 Canada, Nova Scotia 
administrative and 
Australian Pharmaceutical 
Benefit databases 
169, 000 in 
2000 and 155, 
000 in 2003 in 
Nova Scotia, 4, 
800, 000 in 
2000 and        5, 
000, 000 in 
2003 in 
Australia 
Retrospective cohort 
study? 62 % in Nova 
Scotian aged 65 and 
older while 68 % 
Australian are aged 65 
and older 
In 2003 15.5 % in Nova Scotia and 9.2 % in 
Australia, Lorazepam (25 %) most common 
in Nova Scotia while Diazepam (33 %) in 
Australia 
No 
Kassam et al. 2006 Canada, Longitudinal 
National Population Health 
Survey (NPHS) 
9,949 in 94/95, 
10,238 for 
96/97, 10532 
for 98/99 and 
10,828 for 
2000/01 
Prospective cohort 
study, all residents 
aged 18 and older 
7.4 % in 1994/95 and 8.2 % in 2000/01 for 
the 65 and over age group,  
No 
Tamblyn et al. * 2005 Canada, Medical services 
claims databases in Quebec 
253,244 persons Prospective cohort 
study, Community 
dwelling adults 65 
years of age and older 
Overall 27.6 % received at one Rx. For BZP, 
Lorazepam (43.7 5) and Oxazepam (20.2 %) 
were the highest Rx.  
Yes, Injury 
occurrence  
Hagen et al. 2005 Canada, 24 western 
Canadian LTC facilities in 
Alberta 
2,443 residents Interrupted time series 
study,  Long-term care 
residents with mean 
age of 84.51 years 
Urban residents 15.7 % while rural residents 
it was 7.6 % , Lorazepam 72.7 %) and 
oxazepam (10.6 %) were the highest Rx. 
No 
Mamdani et al. 2004 Canada, administrative 
databases of Ontario  
1.4 million 
residents of 
Ontario 
Retrospective cross-
sectional study, adults 
65 years of age and 
older 
17 % in 1993 to 15 % in 2002 Increase in 
proportion of Rx. Of short and medium 
acting increased while long and ultra-short 
acting decreased. 
No 
 
Hogan et al. 2003 Canada, Canadian study of 
health and aging (CSHA) 
from 36 Canadian cities 
1,081 
community 
dwelling and 
institutionalized 
persons 
Prospective cohort 
study, adults 65 years 
of age and older 
Proportion of subjects using BZP at time 1 
and time 2 was similar (26.4% versus 
25.2%) 
No 
Tamblyn et al. * 1994 Canada, Medicare 
registrants made at least 
one visit to a physician  
63,268 
Medicare 
registrants 
Retrospective Cohort 
study, patients 65 
years of age and older 
Over all BZP- 30.8 % while long –acting 
BZP it was 12.9 % 
No 
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Author, year Country, setting Sample size Study Design, 
population 
% of BZP (overall/ specific)  Outcome, 
Yes/No 
Morgan Et al 1998 United Kingdom, Activity 
and aging survey, 
Nottingham 
1,020 
participants  
Prospective Cohort 
study, Community 
dwelling persons aged 
65 and older 
16 % reported using BZP No 
Schjott et al. 1999 Norway, Drug 
administration records of 
31 institutions 
1,062 patients Cross-sectional study, 
Nursing and old age 
home residents aged 
65 and older 
25% patients were on hypnotics out of which 
50% were long-acting BZP, flunitrazepam 
(32%) and nitrazepam (16.9%) were the 
highest Rx. 
No 
Egan et al. * 2000 Canada, Canadian study of 
health and aging (CSHAI) 
from 36 Canadian cities 
1,423 
community 
dwelling older 
Retrospective Cohort 
study, adults 65 years 
of age and older 
Over all BZP- 19.8 % No 
Mamdani et al. 2001 Canada, administrative 
databases of Ontario 
provincial universal drug 
benefit program 
Over 1 million 
residents  
Retrospective cross-
sectional study, adults 
65 years of age and 
older 
25.1 % in 1993 and 22.5 % in 1998, 
Approximately 20 % in those aged 65 to 69 
while 30 % in those aged 85 or older 
No 
Egan et al. * 2001 Canada, Canadian study of 
health and aging (CSHA) 
from 36 Canadian cities 
1,423 
community 
dwelling older 
Retrospective Cohort 
study, adults 65 years 
of age and older 
Use of high daily doses of BZP was 7.9% 
(standard one year prevalence), Lorazepam 
and oxazepam were the highest Rx. 
No 
 
Hogan et al. (86) reported that 21.6% and 4% of seniors from the Canadian study 
of health and aging (CSHA) were using a short or long half-life benzodiazepines, 
respectively, in 2003, while Tamblyn et al. (87) showed a prevalence of 27.6% of at least 
one prescription of benzodiazepine in Quebec residents.  Dailly et al. (88) reported a 21% 
prevalence of chronic use of benzodiazepines and an anti-anxiolytic agent, and a 17% 
prevalence of hypnotic use in the epidemiology of vascular aging (EVA) study in a 
sample of 1,265 elderly persons.  Bastien et al. (89) in Quebec find that nearly 32.6% of 
elderly (aged 55 and older) chronic users of benzodiazepines used them for insomnia 
treatment.    
In the latter study there were only 46 participants, making the results difficult to 
generalize.  Mellinger et al. (90) reported that despite their high risk, 33 % of older adults 
(65 years and older) were using benzodiazepines for the long-term (> 1 year). Gleason et 
al. (91) reported in a cross-sectional community based study, that 22.5% of community 
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dwelling elderly (65 years and more) were using benzodiazepines as hypnotics using a 
sample size of 5,181 elderly.  
Tamblyn et al. (92) also observed that in 1994, 13% of Quebec seniors were using 
long half-life benzodiazepines and 31% were using benzodiazepines for periods 
exceeding 30 days and also observed that Quebec had the highest rate of sedative-
hypnotic drug use in three consecutive national health surveys.  The highest prevalence of 
benzodiazepine use as reported by Tamblyn et al. (87) (27.6%), is concordant with other 
reports from Quebec on the prevalence of benzodiazepine use as per Voyer et al. (93) 
(25.4%), Béland et al. (94) (25.2%) and Fortin et al. (95) (26.2%).  When comparing the 
results provincially across the Canada; the lowest prevalence of use in Alberta was 
reported by Hagen et al. (96)  (urban 15.7% and rural 7.6%), while the highest prevalence 
of benzodiazepines was reported from Quebec by Tamblyn et al. (87). Mamdani et al. 
(43), (41) reported a lower prevalence of benzodiazepines in Ontario than in Québec 
(17% in 1993 and 15% in 2002).  The prevalence of benzodiazepines is higher in Canada 
compared to reports from the United Kingdom by Morgan et al. (97) (16%) and by 
Schjott et al. (98) from Norway showing an overall prevalence of 12.5% in these 
countries.  Lorazepam and oxazepam are the most commonly prescribed benzodiazepines 
in Canada (Table 5). 
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Chapter 3. Insomnia as a prototype disease in older 
adults 
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3.1. Definition 
The nature of insomnia probably contributes to the difficulties associated with its 
treatment.  Polysomnographic studies of patients with insomnia generally show 
abnormalities such as prolonged latency to sleep onset, frequent arousals, and reduced 
amounts of total sleep.  However, objective measures of sleep do not always correlate 
well with the patient's experience of insomnia, which may be partially due to the fact that 
the function of sleep itself is still unknown; making it difficult to pinpoint which objective 
sleep abnormalities contribute to the clinical entity of insomnia (99). 
The DSM-IV and ICD classification systems categorize insomnia as primary when 
the disorder is characterized as not being related to or caused by another sleep, mental, 
medical disorder or effects of a medication (100).  Breathing-related sleep disorder is a 
separate diagnosis, often presenting with insomnia complaints (101).  There is no formal 
category for secondary insomnia. Instead, diagnoses reside within the broad dyssomnia 
section for categories such as Insomnia Related to Another Mental Disorder, Sleep 
Disorders Due to a General Medical Condition, Insomnia Type, and Substance-Induced 
Sleep Disorder, Insomnia Type. 
3.2. Classification of insomnia 
Based on the duration of the symptom, insomnia can be classified as transient, acute, 
or chronic (100, 101). 
A) Transient insomnia is characterized as sleepiness and impaired psychomotor 
performance lasting for less than a week.  This type of insomnia can be caused by 
another disorder, by changes in the sleep environment, by the timing of sleep, 
severe depression, or by stress.  
B) Acute insomnia is the inability to consistently sleep well for a period of less than 
4 weeks.  Acute insomnia is usually related to identifiable factors caused by an 
emotional or physical discomfort.  Examples include acute medical illness; 
changes in the sleeping environment such as noise, light and temperature; self-
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medication; and acute or recurring stress such as work problems, concerns about 
health and marital strife.  There is difficulty in initiating or maintaining sleep and 
the sleep that is obtained are non-refreshing or of poor quality.  
C) Chronic insomnia lasts for longer than 4 weeks.  It can be caused by high levels 
of stress hormones or shifts in the levels of cytokines.  It includes muscular 
fatigue, hallucinations, and/or mental fatigue.  Chronic insomnia implies that 
insomnia is either persistent or recurrent.  Chronic insomnia is complex requiring 
a wide range of disorders to be considered in the search for an underlying cause. 
After establishing the chronicity of the complaint, a differential assessment of 
chronic insomnia can be made on the basis of whether the patient has difficulty in 
falling asleep or difficulty in maintaining or staying asleep. 
3.3. Prevalence of insomnia 
Insomnia is one of the most prevalent health complaints and the most common of 
all sleep disorders in the geriatric population.  A survey in United States reported a 
prevalence of 45% in people aged 65 and older when only one sleep difficulty criteria is 
considered (90).  A cross-sectional study conducted by Voyer et al. (102) in the province 
of Quebec (n = 2,332) among seniors living in long-term care facilities found that 144 
(6.2%) participants had an insomnia disorder according to DSM-IV criteria. 
According to DSM-IV criteria, Ohayon et al. (103) found the prevalence of 
insomnia in only 4.1–6.7% of community dwelling elderly people.  Another prospective 
cohort study conducted in United States for people aged > 65 years found that between 
23% and 34% had insomnia and between 7% and 15% had chronic insomnia (104).  
More than one half of community dwelling older adults aged 65 years or older report 
chronic sleep difficulties (10).  In a review article, Ohayon et al. described estimates of 
prevalence for chronic insomnia ranging from 4.4%-48% in the general population 
depending on the definition used to describe the chronic insomnia, the study type and the 
instruments used to evaluate the insomnia (103). 
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Morin et al. (105) conducted a cross sectional study for 2,000 participants (mean 
age 48.6) for 5 different Canadian regions using a random digit dialing technique to 
interview the participants.  Insomnia disorder was defined according to DSM IV and ICD 
10 criteria.  They reported a prevalence rate of 10.3% for insomnia disorder for the 
province of Quebec.  In the absence of polysomnographic measures, these results may be 
overestimated as sampling techniques used by the authors may possibly include people 
with other sleep problems, like sleep apnea.  We used these estimates for estimating the 
Potential cost saving as this was the only available study for the province of Quebec. 
3.4. Economic burden of insomnia 
Chronic insomnia incurs negative health consequences on quality of life as well as 
a significant economic burden for the individual and for society (106, 107).  One study 
(108), analyzed the economic costs of insomnia for participants in the province of 
Quebec (Canada) differentiating insomnia syndrome (meeting DSM-IV criteria for 
insomnia diagnosis), insomnia symptoms and good sleepers.  The study showed that 
individuals with insomnia syndrome incur significantly enhanced costs due to utilization 
of the health care system.   
Furthermore, loss of productivity over the last 3 months was almost 5 times 
higher for persons with insomnia syndrome than in good sleepers.  The total direct and 
indirect annual costs of insomnia for the province of Quebec were estimated at 6.6 billion 
CAD$, (108).  Although studies have been conducted on the overall economic burden of 
insomnia in Canada, the cost specifically for the elderly population has not yet been 
assessed.   
A few studies conducted in United States (109, 110) have provided data on 
segmented direct and indirect costs and on adverse effects on quality-of-life parameters in 
the elderly.  In addition to the economic burden of insomnia in the population, insomnia 
has also been associated with an increased risk of falls, and aggravates existing health 
conditions (111).  Falls are a common and costly problem in older people. Although most 
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falls are not directly fatal and costly, they are leading cause of injuries and trauma-related 
hospital admissions and increase the economic burden of the patient (112).   
In a survey conducted on 1,526 community-dwelling older adults, various 
insomnia symptoms were significantly related to the number of reported falls and hospital 
admissions (112).  A separate assessment of health care service costs found that nursing 
home care related to insomnia in the elderly amounted to $10.9 billion (91% of all health 
care services related to insomnia, across all age groups) (113).  Sleep disturbances in the 
elderly, and the subsequent disruption of caregivers’ sleep exact a toll on family support. 
Insomnia has been cited as a primary factor in caregivers' decisions to institutionalize an 
elder, with 20.4% (113) and 52% (114) of admissions to long-term care directly 
attributable to sleep disturbances.  
A survey of 1,855 elderly urban residents found that insomnia was a strong 
predictor among males for both mortality and nursing home placement (115).  Insomnia 
may also contribute to cognitive decline (116) and insomnia-induced cognitive 
impairments can confound accurate dementia diagnoses and lead to suboptimal and 
delayed treatment (111).  In a recent study in the United States, after matching and 
regression-based adjustments were made, the direct medical expenditures were $924 
higher for younger patients eventually diagnosed with or treated for insomnia, compared 
with those who were not (117).  
Direct medical expenditures were also $1,143 higher for elderly patients 
eventually diagnosed with or treated for insomnia, compared with elderly patients who 
were not.  There were also differences in indirect costs, specifically, absenteeism costs 
were $ 405 higher for those eventually diagnosed with or treated for insomnia (117).  It is 
more difficult to estimate the true burden of insomnia in the geriatric population because 
the majority of older adults are retired, suffer from co-morbidities (118), and may be 
socially isolated (119) 
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3.5. Treatment options for insomnia 
3.5.1. Pharmacological treatment 
3.5.1.1. Non-prescription medication 
Commonly used non-prescription medications include antihistamines, melatonin 
and valerian (120, 121).  Many people who suffer from insomnia self-medicate with 
over-the-counter products prior to seeking medical advice, usually because they are 
widely available and relatively inexpensive (122, 123).  Among adults aged 60 years and 
older, the most common self-prescribed therapies include alcohol (13%), antihistamines 
(36%), and dietary supplements (11%) (121, 123, 124).   
There is no official indication for the use of over-the-counter medications for the 
treatment of insomnia, and none are approved by Food and Drug Administration (FDA) 
for treating insomnia.  Valerian, also known as nature’s valium, is an herbal preparation 
derived from the root of a plant, Valeriana.  Its sedative effect is attributed to the possible 
gamma amino butyric acid (GABA) like properties but scientific data regarding its safety 
are lacking (125).  
3.5.1.2. Prescription medication 
There are various classes of medication available for the treatment of insomnia.  Lists of 
drug classes with their mechanism of action are provided in  
Table 6. Apart from benzodiazepines newer short-acting non-benzodiazepines such as the 
Z-drugs may be able to induce sleep with fewer side effects than benzodiazepines (126), 
although this remains controversial.   
Table 6  Prescription medications 
Drug Class Mechanism of action & example 
BZD(127) BZD receptor agonist, lorazepam 
Non-BZD (Z-drugs)(127) BZD receptor agonist, zolpidem 
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Melatonin (120) Melatonin  receptor agonist, ramelteon 
Antipsychotics(128) Atypical antipsychotic, olanzapine 
Antidepressant (124) SSRI,  trazodone 
 
Both benzodiazepine and non-benzodiazepine sedative hypnotics act on GABA-A 
receptor sites in the brain, but non-benzodiazepines are more specific in the subunits they 
target.  Developed in the late 1980s, these drugs are now the preferred sedative hypnotic 
drugs for the treatment of insomnia.  In general, these drugs are recommended for short-
term use (7 - 10 days), and treatment should not exceed 4 weeks.  Antidepressants are 
sometimes used to treat insomnia that may be caused by depression (secondary 
insomnia).  In addition to above; melatonin, 5-hydroxytryptamine antagonist and some 
antidepressants with sedating properties are prescribed for the treatment of primary 
insomnia.  
3.5.1.2.1 Use of benzodiazepines: Efficacy  
The clinical efficacy of benzodiazepines is provided in  
Table 7.  Three meta-analyses have analyzed the efficacy of benzodiazepines for the 
treatment of insomnia (129-131).  The first meta-analysis pooled twenty-two randomised 
controlled trials and found that benzodiazepines were superior to placebo in all 4 
outcome measures studied (sleep-onset-latency, total sleep time, sleep efficiency and 
wake after sleep onset) (129).    
Table 7 Clinical efficacy of benzodiazepines 
Ref. 
(Type) 
Population Outcome, Interventions Statistical significance Favours 
Sleep quality 
(132) 
Systematic 
review 
277 people aged 
60 years or over 
with insomnia 
 
7 RCTs in this  
analysis 
Mean subjective sleep-
quality score (measured on 
a 5-point scale) , at least 5 
nights  
3.1 with benzodiazepines 
2.7 with placebo 
Mean effect size 0.37 95% CI 0.01 to 
0.73 
P = 0.04 
benzodiazepines 
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(133) RCT 
Crossover 
design 
3-armed 
trial 
25 people aged 70 
to 89 years with primary 
insomnia  
20 people completed 
at least 1 treatment 
arm 
Subjective sleep quality 
(scale 1–5) , 14 days 
 
3.3 with temazepam 15 mg 
for 14 nights 
2.9 with placebo 
P <0.05 temazepam 
Total sleep time 
(132) 
Systematic 
review 
277 people aged 60 years 
or over with insomnia 
7 RCTs in this  
analysis 
Total sleep time , at least 5 
Nights 
With benzodiazepines 
With placebo 
Mean difference in increased total 
sleep time: 34.2 minutes 
95% CI 16.2 minutes to 52.8 minutes 
P <0.01 
benzodiazepines 
(133) RCT 
Crossover 
design 
3-armed 
trial 
25 people aged 70 to 89 
years 20 people 
completed 
at least 1 treatment arm 
Subjective total sleep time, 
14 days  
6.9 hours with temazepam 
15 mg 
for 14 nights 
6.3 hours with placebo 
P <0.05 temazepam 
Number of awakenings 
(132) 
Systematic 
review 
296 people aged 60 years 
or over with insomnia 
 
6 RCTs in this  
analysis 
Number of awakenings , at 
least 5 nights 
With benzodiazepines 
With placebo 
Mean difference in reduced number 
of awakenings: –0.60 
95% CI –0.41 to –0.78 
P <0.0001 
benzodiazepines 
(133) RCT 
Crossover 
design 
3-armed 
trial 
25 people aged 70 
to 89 years with 
primary insomnia  
20 people completed 
at least 1 treatment 
arm 
Number of awakenings 
(subjective measure) , 14 
days 
1.5 with temazepam 15 
mg for 14 Nights 
2.0 with placebo 
P <0.05 temazepam 
 
Sleep onset latency 
(133) RCT 
Crossover 
design 
3-armed 
trial 
25 people aged 70 
to 89 years with 
primary insomnia  
20 people completed 
at least 1 treatment 
arm 
 
Subjective sleep onset 
latency , 14 days 
25.4 minutes with 
temazepam 15 mg for 14 
nights 
36.8 minutes with placebo 
P <0.05 temazepam 
Sleep efficiency 
(134) RCT 
4-armed 
trial 
78 people aged at 
least 55 years 
(mean age 65 years) with 
primary insomnia  
The remaining 
arms assessed 
CBT and CBT plus 
temazepam 
Change from baseline in 
sleep efficiency , 8 weeks 
From 72.37% to 82.68% 
with temazepam (variable 
dose) 
From 69.11% to 73.39% 
with placebo 
P <0.01 Temazepam 
 
Wake after sleep onset (WASO) 
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(134) RCT 
4-armed 
trial 
78 people aged at 
least 55 years 
(mean age 65 years) with 
primary insomnia  
The remaining 
arms assessed 
CBT and CBT plus 
temazepam 
With pharmacotherapy 
(post treatment) = 55 
minutes 
With placebo (post 
treatment) = 62 minutes 
P <0.05 Pharmacotherapy 
 
The second meta-analysis included one hundred and five studies and found a 
combined weighted mean difference showing that benzodiazepines and non-
benzodiazepines (Z-drugs) had significantly shorter sleep onset latency times compared 
to placebo when measured by polysomnography (WMD: −10.0 minutes; 95% CI: −16.6, 
−3.4; WMD: −12.8 minutes; 95% CI: −16.9,−8.8) or by sleep diary (WMD: −19.6 
minutes; 95% CI: −23.9, −15.3;WMD −17.0 minutes; 95% CI: −20.0, −14.0). The 
improvements measured by sleep diary were more prominent for both drug groups 
compared to polysomnography method (130).  The third meta-analysis confirmed that 
sleep time latency for patients receiving a benzodiazepine was 4.2 minutes shorter than 
for those receiving placebo.   
The total sleep duration (using sleep records) for benzodiazepine groups indicated 
that participants slept for an average of 61.8 minutes (95% CI 37.4 to 86.2) longer than 
those in the placebo groups.   Patients’ estimates of sleep latency were examined and the 
summary estimate of the superiority of benzodiazepines over placebo was 14.3 minutes 
(95% CI 10.6 to 18.0) (131).  There are conflicting recommendations regarding the use of 
benzodiazepines and non-benzodiazepines for the treatment of insomnia.   
For instance, the National Institute of Mental Health Consensus Conference on 
drugs and insomnia suggests that transient and short-term insomnia be treated with p.r.n 
or short term (1-2 weeks) use of benzodiazepines respectively, and that treatment of 
chronic insomnia be limited to benzodiazepine use in minimal effective doses, 
intermittently, or in short courses (135).  The United Kingdom committee on safety of 
medicines (136) and the Royal College of Psychiatrists (137) both recommend that 
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benzodiazepines be prescribed for insomnia “only when it is severe, disabling, or 
subjecting the individual to extreme distress”.  The Drug and Therapeutics Bulletin (138) 
states that benzodiazepines “should only be used when sleep disturbance markedly 
affects the life of an individual or his family, and when other approaches have failed.”   
The 2012 Beers criteria explicitly state that both benzodiazepines and non-
benzodiazepines (Z-drugs) should be avoided at all costs for the treatment of chronic 
insomnia in the elderly (139). 
3.5.2. Non-pharmacological treatment 
Cognitive–behavioural therapy (CBT) is the evidence-based treatment of choice 
for several psychiatric disorders, including insomnia (140, 141).  Cognitive-behavioural 
therapy refers to any treatment based on the idea that psychological problems arise as a 
result of the way in which people interpret or evaluate situations, thoughts, and feelings, 
as well the behaviors that stem from these evaluations (141).  Cognitive behavioural 
therapy for insomnia (CBT-I) is a multi-component therapy, based on targeting factors 
that interfere with initiating and maintaining sleep.   
The therapy specifically addresses the multiple putative causes and perpetuators 
of insomnia (142).  The underpinnings of CBT-I flow from (a) the application of both 
operant and classical conditioning paradigms in the form of stimulus control instructions 
(143); (b) the focus on sleep-interfering behaviors in the form of sleep hygiene (144); (c) 
the recognition of and focus on reducing the hyper arousal features of insomnia (145); (d) 
the improvement of circadian and sleep homeostasis regulation of sleep with sleep 
scheduling and limited, partial sleep deprivation (146); and (e) the adaptation of cognitive 
therapy to insomnia (147).  A stepped care model known as brief behavioural therapy for 
insomnia (BBTI) is a shorter version of the psychological interventions and can be 
delivered by primary care nurses and general practitioners. The efficacy of brief 
behavioural treatment is statistically and clinically significant and sustainable for six 
months compared to information controls (148). 
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3.5.2.1. Cognitive behavioural therapy: Efficacy  
A growing body of evidence confirms the efficacy of behavioural interventions for 
persons with insomnia (149-153). Different measures of efficacy are presented in  
Table 8.  Montgomery et al. (150) conducted a systematic review and reported that there 
was an improvement in all sleep variables for both post treatment and long term effect.  
Table 8 Clinical efficacy of cognitive behavioural therapy 
Ref. 
(Type)                                  Population             Outcome, Interventions                         Statistical significance         Favours 
 
Sleep quality 
(154) RCT 47 hypnotic-dependent 
people with 
chronic insomnia 
aged 50 to 85 
years, mean age 
 64 years 
Mean subjective sleep-quality score 
(measured on a 5-point scale) , at least 5 
nights  
3.60 with CBT 
3.30 with placebo 
Not reported Not applicable 
Total sleep time 
(154) RCT 47 hypnotic-dependent 
people with 
chronic insomnia 
aged 50 to 85 
years, mean age 
 64 years 
With  CBT = 408 minutes 
With placebo = 404 minutes 
Not reported Not applicable 
Number of awakening 
(154) RCT 47 hypnotic-dependent 
people with 
chronic insomnia 
aged 50 to 85 
years, mean age 
 64 years 
Number of awakenings , at least 5 nights 
With CBT = 1.80 
With placebo = 1.77 
Not reported Not applicable 
Sleep onset latency 
(154) RCT 47 hypnotic-dependent 
people with 
chronic insomnia 
aged 50 to 85 
years, mean age 
 64 years 
Change from baseline in sleep  
onset latency , 8 weeks 
From 44.61 minutes to 19.85 
minutes with CBT 
From 41.42 minutes to 30.50 
minutes with control  
 
P <0.05 CBT 
(155) RCT 
 
35 people aged >60 
years with 
DSM-IV criteria for 
primary insomnia 
Change in self-reported mean  
time to fall asleep , 4 weeks 
From 38.32 minutes to 16.80 
minutes with brief behavioural 
treatment for insomnia (BBTI) 
From 29.67 minutes to 26.85 
P <0.05 BBTI 
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minutes with information-only 
control 
Sleep efficiency 
(153) Systematic 
review 
Participants 
aged at least 55 years 
6 RCTs in this 
analysis 
Ratio of time asleep to time in 
Bed with CBT 
with no treatment 
Mean effect 
size 0.38 
95% CI 0.12 
to 0.65 
P <0.005 
CBT 
(154) RCT 
 
47 hypnotic-dependent 
people with 
chronic insomnia 
aged 50 to 85 
years, mean age 
64 years 
Change from baseline in sleep  
efficiency , 8 weeks 
From 72.87% to 86.80% with 
CBT 
From 72.36% to 79.32% with 
control  
P <0.05 CBT 
Wake after sleep onset (WASO) 
(154) RCT 
 
47 hypnotic-dependent 
people with 
chronic insomnia 
aged 50 to 85 
years, mean age 
64 years 
Change from baseline in sleep  
efficiency , 8 weeks 
From 71.55 minutes to 26.92 
minutes with CBT 
From 58.07 minutes to 37.56 
minutes with control (sham 
biofeedback) 
P <0.05 CBT 
(155) RCT 35 people aged >60 
years with 
DSM-IV criteria for 
primary insomnia 
Change in self-reported WASO  
, 4 weeks 
From 61.21 minutes to 27.72 
minutes with brief behavioural 
treatment for insomnia (BBTI) 
From 47.91 minutes to 35.5 minutes 
with information-only control 
P <0.05 BBTI 
 
Wake after sleep onset with diaries improved from 22 minutes to 13 minutes 
while with polysomnography it improved from 24 to 10 minutes.  Total wake time 
improvement with diaries was 62 minutes and 38 minutes with polysomnography.  Sleep 
duration was improved by 32 minutes with diaries and by 19 minutes with 
polysomnography.  Sleep efficiency was improved by 7.5% according to sleep diaries 
and by 6.3% by polysomnography. 
Erwin et al. (153) conducted a meta-analysis including twenty-three randomised 
controlled trials.  Overall statistically significant effects were observed for sleep quality 
(7 studies; fixed-effect ES 0.76, 95% CI: 0.48, 1.03), sleep latency (21 studies; random-
effects ES -0.50, 95% CI: -0.82, -0.19, p<0.001), sleep efficiency (8 studies; random-
effects ES 0.74, 95% CI: 0.11, 1.38, p<0.001) and wake after sleep onset (15 studies; 
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fixed-effect ES -0.64, 95% CI: -0.82, -0.47, p=0.86), but not for total sleep time.  In a 
systematic literature review including 6 randomised controlled trials with participants 
aged at least 55 years, the authors reported  mean effect size of 0.38 95% CI 0.12 to 0.65 
(P <0.005) for sleep efficiency with cognitive behavioural therapy compared to no 
treatment. 
3.6. Efficacy and clinical effectiveness of pharmacological versus 
non-pharmacological treatments for insomnia 
Wu et al. (156) conducted a randomised clinical trial in 2006 comparing 
cognitive-behavioural and pharmacological therapy for chronic insomnia.  Seventy-one 
patients with chronic insomnia were randomly divided into 4 groups and either received 
cognitive-behavior therapy (CBT, n = 19), pharmacological therapy (PCT, n = 17), CBT 
plus medication (Combined, n = 18) or placebo (n = 17). The treatments lasted for 8 
weeks with follow-ups conducted at 3 and 8 months.  On the day after treatment ended, 
all patients were assessed using a polysomnography (PSG), a sleep diary and a 
psychological assessment. 
Patients who received combined treatments did not have as good a long-term 
outcome as those who receive behavioural therapy alone (157), although the reasons for 
this finding have not been clearly elucidated (46). Cognitive behavioural therapy patients 
showed the greatest improvements in sleep parameters at 3-month follow-up. The 
subjective and objective sleep-onset latency in the CBT group was less than 30 minutes, 
while sleep efficiency and total sleep time exceeded 85% and 382 minutes respectively.  
For patients on benzodiazepines, the average sleep-onset latency was 47.2 
minutes, sleep efficiency was lower than 80% and total sleep time was 368 minutes 
(156). There was a statistically significant difference between the two groups for sleep 
latency, total sleep time and sleep efficiency using both outcome measures 
(polysomnography and sleep diaries). However Mitchell et al. (158) reported that the 
quality of the evidence comparing benzodiazepines to cognitive behavioural therapy for 
insomnia in the short term is of very low grade, meeting 3 of 9 quality points in the 
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GRADE system, making it difficult to draw firm conclusions about the superiority of 
CBT over benzodiazepines. 
Erwin et al. conducted a meta-analysis on the short-term efficacy of 
pharmacotherapy (benzodiazepines or benzodiazepine receptor agonists) compared with 
behavioural therapy (stimulus control and sleep restriction) for primary insomnia in 21 
studies using prospective measures and within-subject designs (159). Comparable short-
term outcomes were seen for both pharmacotherapy and behavioural therapy except in 
sleep latency where behavioural therapy revealed a greater reduction in sleep latency. 
Post-treatment weighted-effect sizes included sleep latency (pharmacotherapy Cohen’s d 
= 0.45, behavioural therapy Cohen’s d = 1.05), sleep quality (pharmacotherapy Cohen’s d 
= 1.20, behavioural therapy Cohen’s d = 1.44), wakefulness after sleep onset 
(pharmacotherapy Cohen’s d = 0.89, behavioural therapy Cohen’s d = 1.03), and total 
sleep time (pharmacotherapy Cohen’s d = 0.84, behavioural therapy Cohen’s d = 0.46) 
(159).  
A different meta-analysis of 59 studies assessing non pharmacologic treatment of 
chronic insomnia found that stimulus control and sleep restriction techniques were most 
helpful in producing improvements over an average six-month follow-up period, but 
sleep hygiene treatment alone was not deemed effective (160).  The American Academy 
of Sleep Medicine published two systematic reviews and concluded that CBTI leads to 
significant improvements in the primary presenting sleep complaint (sleep initiation 
and/or maintenance) with sustained improvement seen for 6–24 months post-treatment 
(161). Clearly, efficacy coupled with minimal side effects makes behavioural techniques 
highly recommended for treating insomnia; however, factors such as cost, lack of 
availability, and potential problems with patient motivation and compliance make the use 
of behavioural techniques difficult as first line treatment (46).  
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3.7. Cost-effectiveness of treatment options for insomnia 
Although emerging studies have compared the clinical effectiveness of various 
interventions for the treatment of chronic insomnia in older adults (134, 151, 157, 162), 
data on the cost-effectiveness of treatment options in chronic insomnia are scarce.  Some 
health technology reports exist showing the cost effectiveness of various non-
benzodiazepine drugs (163) in the treatment of chronic insomnia.  For instance, studies 
have been conducted on Eszopiclone, a z-drug hypnotic (164), psychological treatment in 
combination with benzodiazepine use (165), and newer hypnotic drugs (Zopiclone, 
Zolpidem, Zaleplon) versus benzodiazepines (166).  To our knowledge, no economic 
evaluation exist comparing cognitive behavioural therapy alone versus benzodiazepines 
in the treatment of chronic insomnia in geriatric populations. 
3.8. Current scenario in Canada 
Despite the evidence of clinically equivalent benefit with less adverse events 
(167, 168), and maintained clinical benefits over a longer period of time (134), cognitive 
behavioural therapy is under-used in Canada (169).  Health care policy likely contributes 
to the underuse of cognitive behavioural therapy in Canada.  Medical visits, medications, 
and “medically necessary” expenses are covered by the Canada Health Act (24), whereas 
psychological services are not (170).  Provinces fund psychotherapy administered by 
physicians, or in the case of non-physician therapists, those employed by public 
institutions (170).  Psychotherapy may be covered by private insurance, but most fees are 
paid for by the individual (171). 
3.9. Rationale for the study 
Non-pharmacological interventions such as cognitive behavioural therapy are as 
effective as pharmacological treatments in the management of chronic insomnia in older 
adults over the short term (172-174), and in some cases are reported as superior over the 
long term (134).  Consensus statements in Canada, as well as other treatment guidelines 
(175) (176) that examine the diagnosis and treatment of insomnia in the elderly 
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recommend the initial use of non-pharmacological interventions.  Unfortunately, use of 
cognitive behavior therapy remains limited.  
Perlis and colleagues (174) discuss reasons for this gap, including a lack of 
trained providers, cost, lack of third party reimbursement and lack of understanding of 
the treatment methods.  Despite their short-comings, and strong associations with falls, 
benzodiazepines continue to rank among the top five medications consumed by the 
geriatric population (85). Furthermore, studies suggest that new benzodiazepine 
prescriptions are dispensed at a rate of 6% per year to the elderly, and that primary care 
practitioners are responsible for 87% of these new prescriptions (177).   
The use of benzodiazepine drugs for the treatment of chronic insomnia is known 
to increase the risk of falls by 57% in older adults and also incurs a greater risk of 
cognitive impairment.  The Canadian Agency for Drugs and Technologies in Health 
(CADTH) has suggested that, although benzodiazepines are inexpensive, they may carry 
an additional hidden cost in the increased health care resources that are used to treat 
adverse events in the elderly.  To date, no such economic evaluation has been conducted 
to investigate this hypothesis. 
 As of March 2012, even the short-acting formulations of benzodiazepines appear 
on the updated Beers list of drugs to avoid in the elderly for treatment of insomnia. 
Despite these warnings, prevalence rates of benzodiazepine use among Canadian seniors 
persistently hover between 17-33% depending on the province and geographic location. 
Studies suggest that new benzodiazepine prescriptions are dispensed at a rate of 6% per 
year to the elderly, and that primary care practitioners are responsible for 87% of these 
new prescriptions.  As a result, benzodiazepines continue to rank among the top five 
medications consumed by the geriatric population, according to a report published by the 
Canadian Institute for Health Information (CIHI).  
The most common indication for benzodiazepine therapy in the elderly is chronic 
insomnia.  This disease is characterized by difficulty initiating or maintaining sleep over 
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a period of at least 30 days. Insomnia leads to daytime fatigue, impairs cognitive and 
physical performance, diminishes quality of life, and contributes to motor vehicle 
accidents and falls.  A recent Canadian population-based survey estimated a 10% 
prevalence of chronic insomnia among community-dwelling older adults, though the 
prevalence may range from 4-48% depending on the population studied and the definition 
used.  
Of the different therapeutic options that exist, drug treatment with 
benzodiazepine-receptor agonists and cognitive-behavioural therapies are equally 
efficacious for treating insomnia in the elderly.  The problem is that access to cognitive-
behavioural therapy is not supported by provincial insurance coverage for seniors.  Thus 
benzodiazepines continue to be prescribed as first-line therapy despite their higher risk of 
falls. 
In Canada, fall prevention figures prominently among public health priorities to 
reduce disability among a growing aged population.  One-in-three older adults are 
expected to fall per year, with 20% of falls resulting in an emergency room visit.  In 
2009, there were 53,545 fall-related hospitalizations among Canadian seniors, costing 
approximately $30,000 each (178).  
Most recommended fall prevention programs include a medication review 
component.  Gradual withdrawal of psychotropic medication yields an anticipated 66% 
reduction in the rate of falls.  The prescription of benzodiazepine drugs for the treatment 
of chronic insomnia therefore runs counter to the general goal of fall prevention.  We 
therefore intend to conduct a cost consequence and cost-utility analysis taking into 
account the predicted incidence and costs of falls associated with both treatments.  A 
potential cost savings analysis was also conducted to examine the financial repercussions 
of a new government reimbursement strategy for cognitive behavioural therapy for 
treating geriatric insomnia.  
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Chapter 4. Objective of the study 
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4.1. Overall objective of the study 
To examine the cost-effectiveness of benzodiazepines versus cognitive 
behavioural therapy for the long term management of insomnia in older adults 
4.2. Specific research question 
To what extent is the treatment cost of cognitive behavioural therapy offset by 
fewer drug-induced falls compared to treatment with benzodiazepines in older adults with 
insomnia over a one-year period? 
4.3. Hypotheses to be tested 
1. When the costs of falls are accounted for, the average per person cost of cognitive 
behavioural therapy will be less than benzodiazepine therapy. 
2. When the quality of life impact of falls is accounted for, the average cost per 
quality adjusted life year resulting from treatment with cognitive behavioural therapy will 
be less than the average cost of a quality adjusted life year for older persons treated with 
benzodiazepines to treat chronic insomnia. 
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Chapter 5. Methods: Cost consequence analysis 
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5.1. Study Question 
To evaluate the potential cost saving by the utilization of cognitive behavioral 
therapy over benzodiazepines use in older adults aged 70 years and over for treating 
insomnia. 
5.2. Economic Evaluations chosen 
We conducted a cost consequence analysis as an intermediate step in reporting the 
cost utility analysis, with the outcomes and costs presented in a disaggregate form to 
improve the reporting transparency. 
5.3. Target Population 
 Target population of interest was older adult’s aged 70 years and older suffering 
from insomnia in Canada as of March, 2012 (179). 
5.4. Comparators 
 A 6-week course of cognitive behavioural therapy (CBT) were compared to single 
dose of 0.5 mg. lorazepam (benzodiazepine) per day over a period of 1 year, as an 
equally effective treatment alternative for adults aged > 70 with chronic insomnia. 
5.5. Perspective 
This study was conducted from a Canadian health payer’s perspective with only 
the cost of health service resources being considered.  
5.6. Time Horizon 
The time horizon chosen for the model was a period of 1-year.   
5.7. Discounting 
 As the time horizon was one year, we did not discount costs associated with the 
competing interventions. 
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5.8. Study design 
Cost consequence analysis (CCA) compares alternative interventions in which the 
components of incremental costs and consequences are listed without aggregation.  A 
cost consequence analysis was conducted to model the costs of benzodiazepine treatment 
versus a 6-week course of cognitive behavioural therapy (CBT), as benzodiazepines 
increases the risk of falls in adults aged > 70 with chronic insomnia (180).  The main 
outcome was cost per year for the two competing interventions, including the cost of falls 
related to treatment. 
5.9. Modelling 
A hypothetical analytic decision tree was constructed for two different treatment 
scenarios for insomnia: pharmacologic treatment with benzodiazepines, and non-
pharmacologic treatment with CBT.  Figure 1depicts how a cohort of seniors might travel 
through the decision tree.  The experience of chronic insomnia may lead the patient to 
consult their general practitioner and obtain a prescription for a benzodiazepine. 
Alternatively, after consultation, the patient may elect a trial of cognitive behavioural 
therapy instead of pharmacologic management.  Of course, in many instances 
professional consultation is not sought, or treatment is not adhered to, resulting in 
symptom persistence (untreated insomnia).  Our model assumes that all seniors with 
chronic insomnia seek and adhere to treatment.  
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Health states of the analytic model are based on how seniors would transition 
between healthcare settings once they experienced a fall that would result in either an 
emergency room visit or hospitalization.  The transition between the various medical 
settings is based on transition probabilities.  These are used to quantify the likelihood of 
the occurrence of an event over a particular period that is captured by the model.  The 
time period chosen for the model is 1-year.   
5.10. Model input parameters 
5.10.1. Probability of falls in older adults 
5.10.1.1. Base case 
The estimation of transition probabilities for falls and fractures was estimated 
from the odd ratios (60, 181). First, we determined the proportion of seniors falling in the 
general population.  For this base-case, we estimated a 30% incidence of falls in adults 
70+ over a 1 year-period, based on data from the Public Health Agency of Canada (178).  
Data from the Public Health Agency of Canada report come from the Discharge 
Abstract Database.  The analyses use an episode-based methodology, which has an 
advantage over separation‐based methodology, as the rates associated with hospital 
separations tend to be higher than the rates associated with episodes of care.  This can 
lead to an overestimate of the demand for care, and an underestimate of the resource 
utilization involved in treating falls in acute care hospitals (i.e., length of stay).  Thus, 
shifting from separations to episodes of care provides a more comprehensive view of the 
extent of acute care involved in treating fall-related hospitalizations.  
The 30% 1-year estimate of falls in the older population that we used for the 
model has been confirmed in other countries such as the United States with large 
population-based studies such as the Women’s Health Initiative (n=22,774 participants 
aged 70-79) (182).  The Women’s Health Initiative was a longitudinal study that recruited 
volunteers and thus cannot be fully representative of the population from which it is 
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drawn.  Because of the selection process for both the dietary and hormone trials, this 
study would be expected to have more women with healthy life styles thus having a 
disadvantage of selection Potential cost saving analysis.  Also data from this study is 
limited to women only.  We did not find any population-based studies of the prevalence 
of falls in older Canadian men, so have assumed that the estimate is similar to women 
based on data from the Public Health Agency of Canada.  
5.10.1.2. Prevalence of falls with benzodiazepine treatment 
The estimate for the increased risk of falls from benzodiazepine use was derived 
from the most recent meta-analysis indicating that the use of BZD increases the risk of 
falls by 1.57 (95% confidence interval, 1.23-1.77) (183).  A primary strength of this study 
was the use of Bayesian methodology, which allowed incorporation of information from 
previous meta-analyses with more recently completed studies to evaluate the level of 
association between drug classes and experiencing a fall.  Although the number of new 
studies included was small for every drug class assessed, the total number of additional 
participants included in the meta-analysis was greater than that in the previous meta-
analyses by Leipzig et al. (62).    We used the Bayesian pooled estimate for the increased 
risk of falls from benzodiazepine use from the Woolcott et al. meta-analysis (OR 1.57), 
but in order to account for uncertainty, we enlarged the bounds of confidence interval 
(1.23 -1.77) from the Bloch F et al. study (61). Odd ratios were converted to probabilities 
using the equation from Rothman’s Textbook of Modern Epidemiology (184). 
  p1/ (1- p1) 
Equation 1  Odds ratio =   
     p2/ (1- p2) 
 
Where p1 is the probability for the first group, and p2 is the probability for the second. 
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For example, if an increased risk of falls associated with benzodiazepines is reported as 
an odds ratio of 1.57, then the probability of falls due to benzodiazepines, assuming a 
base case probability of falls (p2) of 0.30, will be: 
 
 
 
 p1/ (1- p1) 
1.57     =                             i.e. 0.42 46* 1.57 = (p1 / 1-p1) 
         (0.3/0.7)  
 
That is 0.6848 = 1.6846p 
 
                  0.6848 
Or p =                                                 i.e. p = 0.40 
       1.6848 
 
 
5.10.1.3. Prevalence of falls with cognitive behavioural therapy 
Since CBT is not associated with adverse events, we assumed that the proportion 
of seniors falling following the use of CBT would be the same as that of seniors not 
suffering from insomnia (base case).   
5.10.2. Probability of visiting the emergency room or being hospitalized 
The Ontario injury prevention resource center reports that 55% of the emergency 
room visits by seniors aged 65 years and above are due to falls and of these, 23% require 
hospitalization (185).  In a recent longitudinal cohort study of elder fallers presenting to 
the emergency room conducted in British Columbia, the authors reported that from 
November 2007 to November 2008, there were 70,251 visits to the Vancouver general 
hospital emergency department.  Among all visits by persons ≥70 years of age 
52 
 
(n = 7,764), 1,484 (19%) were fall-related.  The difference between these 2 studies may 
be due to the fact that exclusion criteria were stricter in the British Columbia study (186). 
The findings from the British Columbia cost saving study are concordant with a 
review article from Finland, which concluded that approximately 20% of falls in the 
elderly require medical attention.  Among the 20% of falls resulting in emergency room 
care for injury (187) 8% require hospital admission.  Review articles are often written by 
one or two "experts" in a field.  This leads to potential bias, including the influence of the 
authors' personal viewpoints, gaps in literature searching practices that may further lead 
to the omission of relevant research, errors in the translation of data from the primary 
literature to summarization in the review, misrepresentation or misinterpretation of 
original source data.  We therefore used data from the British Columbia cost saving study 
for the purposes of our analyses for two main reasons: first it was a recent study and 
second, it was a prospective study. 
5.10.3. Probability of hip-fracture after falls 
The prevalence of hip-fractures varies and increases as a function of age.  A large 
prospective cohort study conducted in the United States reported a prevalence rate of hip 
fractures as .022 (2.2%) among community dwelling elderly with a mean age of 79 years 
(181).  This is one of the largest prospective studies to describe the risk of hip fracture in 
a diverse cohort (12 sites in United States) of older nursing-home-eligible persons living 
in the community (number = 5,187 and follow up for 7 years).  
Another study using self-report data from 5,630 community-dwelling elderly 
people 70 years or older conducted in the United States reported a baseline prevalence of 
0.042 (188).  This study has several primary strengths.  First, because they used a large, 
nationally representative cohort of community-dwelling elderly people (n = 5,630), their 
results are more likely than the results of hospital-based studies to be generalizable to the 
overall community-dwelling elderly population.  
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Second, they assessed risk factors before the occurrence of hip fractures; this 
eliminated recall Potential cost saving analysis, which can be problematic in case–control 
studies. Third, they included a number of socioeconomic factors.  A limitation of this 
study is that they used self-reported information on hip fracture and comorbid conditions.   
In addition, their exclusion of individuals with proxy respondents may have 
resulted in underestimations of the magnitude of some risk factors.  Another recent 
longitudinal cohort study of elder fallers presenting to the emergency room in British 
Columbia cost saving reported that among the 20% of falls resulting in emergency room 
care, 5% incurred treatment for hip fractures (189). For the purposes of our study, we 
took an average of the hip fracture rate reported from the above studies and used an 
estimate of 0.036. 
5.10.4. Direct health-care costs 
Health system cost data included the costs of medication/therapy, consultations 
with physician/psychologists, and health care costs related to emergency room visits and 
hospitalizations due to fall injuries.  Unit costs were based on 2012 data from the 
Government of British Columbia cost saving (190, 191).  We took cost data from British 
Columbia cost saving in accordance with the prospective micro-costing study on the cost 
of fall-related presentations to the emergency department in British Columbia cost 
saving.  
The average cost of benzodiazepines was based on a report published by Brogan 
International on Canadian Pharmaceutical Trends stating that lorazepam was the most 
commonly prescribed benzodiazepine in 2011 in Canada (192). The cost of lorazepam 
0.5 mg qhs was used to represent the average cost of a benzodiazepine prescription.  The 
average dispensing fee of $10 Canadian per month were taken from Patented Medicine 
Prices Review Board (193).  The reimbursement rate of generic lorazepam for a daily 
prescription for 30 days were calculated and a dispensing cost of CAD$ 10 per month 
was added to drive the total yearly medication cost.  
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Cognitive behavioural therapy costs were derived from the British Columbia cost 
saving hourly reimbursement rate for psychologists, which is CAD$ 160 per hour (Table 
9).  Hourly wages were multiplied by 6 for the usual number of sessions for CBT and 
divided by 4 as CBT is generally delivered to groups of 4 individuals.  The total cost of 
cognitive behavioural therapy was calculated by adding the cost of the general physician 
visit and the cost of the group sessions with the psychologist. 
5.10.5. Costs of falls and hip-fracture 
Health system costs including emergency room visits, hospitalization, and the cost 
of surgery and rehabilitation for hip fractures were derived from Woolcott et al.’s 1-year 
micro-economic cohort study of elder fallers presenting to the emergency room in British 
Columbia cost saving (186).   This was a 1-year longitudinal cohort study of elder fallers 
presenting to the emergency room in British Columbia cost saving.  Data were collected 
prospectively on seniors (>70 years) with injurious falls.  
The population sample of 101 patients was representative of the general older 
population as the authors compared them with three other samples of ‘senior emergency 
department fallers’. The data for the study sample fell within one confidence interval of 
the data for the three comparison groups. Specifically, the authors compared the sample 
against (a) all senior fallers who presented to the Vancouver general hospital emergency 
department in 2008, (b) a sample of 58 consecutive fallers recruited at the Vancouver 
general hospital emergency department in 2003, and (c) a highly cited large randomised 
controlled trial that recruited senior fallers in the United Kingdom (194).   
There were no statistical differences between the recruited population and the 
global population of elderly fallers to the Vancouver general hospital.  The British 
Columbia cost saving study has several strengths including accurate capture of costs 
prospectively and in real-time for each participant (micro costing).  The costing approach 
used in this study has an advantage over administrative data that has been shown to 
underestimate the incidence of falls (195).  As a result, rather than extrapolating the care 
and costs of care from Case Mix Group data or Resource Intensity Weight data, they 
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estimated micro cost according to the care received by each participant and were not 
relying on coding/chart review.   
This study also has some limitations, the most important of which is an 
underestimation of the costs associated with falls. Participants were followed until 
discharge from the emergency department, hospital, or rehabilitation facility and no 
subsequent costs incurred were included in their estimates. If post hospital costs had been 
included, the cost estimates may have been larger. Also, the British Columbia cost saving 
study did not recruit non-English speaking or cognitively impaired individuals who may 
have different fall-related health resource utilization and costs compared to the sample 
population. All cost estimates and parameters including estimates of uncertainty are 
provided in the Table 9. 
Table 9 Parameters used in the decision tree model, including estimates of 
uncertainty 
Variable Base-case 
value 
Range of 
uncertainty 
used for 1-
way 
deterministic 
sensitivity 
analysis 
Probability 
distribution 
(standard 
deviation) 
used for multi-
way 
probabilistic 
sensitivity 
analysis 
Reference 
Probability parameters     
    Baseline probability of falls for 
an older adult 
0.30 0.28 - 0.32 0.05, Beta (178) 
    Probability of emergency 
department  visit without 
hospitalization after a fall* 
0.124 0.10 – 0.30 0.02, Beta (186, 196, 197) 
    Probability of a hospitalization 
without hip fracture post-fall* 
0.04 0.02 – 0.06 0.005, Normal (186, 198) 
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    Probability of a hospitalization  
for a hip fracture post- fall* 
0.036 0.022 -0.042 0.005, Normal (181, 186, 188) 
    Incremental risk of falls due to 
benzodiazepine 
1.57 1.23 -1.77 0.1, Beta (60, 61) 
    Probability of falls with 
benzodiazepine 
0.40 0.34 -0.43 0.05, Beta (60, 61, 199) 
Costs (CAD $)     
    Benzodiazepine acquisition+/year 14.16 $ 
(0.0388/pill)
- - (200) 
    Dispensing cost/year 10.18 $ - - (201) 
    Total drug cost/year 136.32 $ 134.54 -150.13 0.5, Gamma (201-203) 
    GP single consultation for 
insomnia 
94.67 $ 68.00 -200.00 10, Gamma (204-206) 
    Single psychologist session 160.00 $   (191) 
    Total cost for a 6-week group 
cognitive behavioral therapy 
program++/person 
240.00 $ 120.00 – 
270.00 
20, Normal (191, 207, 208) 
     
    Emergency room visit for a fall 708.00 $ 636.00 – 
779.00 
65, Gamma (186, 209, 210) 
    Fall-related hospitalization 30,851.00 $ 27,765.00 -
33,936.00 
2,900, Gamma (186, 209, 210) 
    Hospitalization for hip fracture 41,509.00 $ 37,358.00 – 
45,659.00 
3,900, Gamma (186, 209, 210) 
 
5.10.6. Sensitivity analysis for the cost consequence analysis 
Sensitivity analysis isolates study variables or parameters, changes their values, 
and recalculates the study results.  This process identifies the parameters with the most 
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influence over the summary measure (or result) while assessing the impact the 
intervention can have by using varied parameters.  Sensitivity analyses are conducted to 
test the overall robustness of the results of the model.  Testing the robustness of the 
results enhances the credibility of the study.   In seeking to address parameter uncertainty, 
both deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA) 
were conducted as per recent NICE recommendations (211).  
Sensitivity analyses were conducted for both probability and cost parameters. 
Upper and lower bounds for the base case probability of falls (0.28- 0.32), the probability 
of an emergency room visit due to falls (0.10 – 0.30), the probability of a hospitalization 
due to falls (0.02 – 0.06) and the probability of hip fractures due to falls (0.022 – 0.042) 
were derived from values in our literature review.  The cost of medications including 
dispensing cost (CAD$ 108.92 – CAD$ 162.50), general physician visits (CAD$ 68.00 – 
CAD$ 200.00), psychologist visits and overall cost of cognitive behavioural therapy 
(CAD$ 120.00 - CAD$ 270.00) were calculated for each province of Canada and upper 
and lower bounds were used for the sensitivity analysis (Table 9).  
Differences in provinces’ per diem costs were used to calculate the upper and 
lower bound costs for an emergency visit (CAD$ 606.60 - CAD$ 741.40), cost of 
hospitalization (CAD$ 26,426.70 – CAD$ 32,299.30) and cost of hip fracture (CAD$ 
35,556.30 - CAD$ 43,457.19).   Cost of hospitalization and hip fracture was highest in 
Yukon and Northwest Territories while least in Prince Edwards’s islands across Canada.  
Aggregate, Ward and ICU Per Diem costs per province were taken from Canadian 
institute for health information (CIHI) Table 10.   
Data for the distribution in probabilities and cost variations for conducting 
sensitivity analysis are shown in Table 10 and Table 11.  We took the average per diem 
cost for hospitals across the Canada to see the uncertainty around the cost parameters.  
Aggregate data (ICU plus hospital bed) were the highest (+11.7% higher for 
Newfoundland than British Columbia cost saving), (but if we include Yukon and the 
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Northwest Territories it would be 67% higher) while the lowest bracket of change in 
health resource costs across Canada was for PEI (-23% in Prince Edward Island). 
Table 10 Aggregate, ward and ICU per diems, by number of beds, by 
province/territory and Canada, 2009-10 
Aggregate (Ward & ICU Combined) Hospital Per Diems, by Number of Beds, by Province/Territory 
and Canada, 2009-10 (CAD $) 
Province 0-50 Beds 
51-150 
Beds 
Greater than 150 
Beds 
Provincial 
Average 
Newfoundland 1,095 1,398 1,272 1,273
Prince Edward Island       873
Nova Scotia 575 811 1,219 977
New Brunswick 701 1,043 1,109 1,047
Ontario 791 924 1,129 1,086
Manitoba 730 821 1,308 1,118
Saskatchewan 687 1068 1,306 1,187
Alberta 869 1167 1,273 1,138
British Columbia cost saving 995 1028 1,224 1,139
Northwest Territories       1,905
Yukon 1,492     1,492
Canada 827 973 1,178 1,105
CIHI 2012.
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Table 11 Provincial variations in cost parameters 
Province Total medication cost 
(in CAD $) 
Primary care 
visit / visit 
(in CAD $) 
Psychologist 
fee / hour 
(in CAD $) 
Total cost of a 
6 week course 
of CBT* 
(in CAD $) 
Drug 
acquisition 
cost/ tablet 
Dispensi
ng cost / 
Rx. 
Total 
cost/ 
year 
 
Quebec 
0.035 8.00 109.00 75.66 125.00 187.50 
Ontario 
 
0.035 10.12 134.00 77.20 140.00 210.00 
British 
Columbia  
0.037 10.18 136.00 94.67 160.00 240.00 
Nova Scotia 0.035 10.62 140.00 123.40 150.00 225.00 
Alberta 0.035 11.00 145.00 84.67 180.00 270.00 
Manitoba 0.039 11.31 150.00 74.15 155.00 232.50 
Prince 
Edward 
Island 
0.038 7.94 109.00 68.00 100.00 150.00 
Saskatchewan 0.035 9.61 128.00 65.10 95.00 142.50 
NWT and 
Nunavut 
Not 
reported 
Not 
reported 
Not 
reported 
114.28 Not reported Not reported 
New 
Brunswick 
Not 
reported 
8.59 Not 
reported 
120.00 80.00 120.00 
Newfound 
land & 
Labrador 
0.036 7.94 108.00 115.21 150.00 225.00 
Yukon Not 
reported 
Not 
reported 
Not 
reported 
200.00 100.00 150.00 
 
* Psychologist fee/hr. X 6 / 4 = $ / person 
Each parameter was studied to estimate the type of distribution and a 
corresponding type of distribution was assigned to each parameter. For example if the 
parameter was normally distributed then the normal distribution was assigned and; if the 
parameter was positively skewed then the gamma distribution was assigned to conduct 
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probabilistic sensitivity analysis.  Benzodiazepine- like drugs (Z-drugs) are commonly 
prescribed drugs for the treatment of insomnia in the elderly, and are gradually replacing 
benzodiazepines in many provinces as the most frequently prescribed medication for 
insomnia.  Although not formally studied in meta-analysis, research suggests that the 
hypnotic effect of z-drugs incurs a similar risk of falls (212).  Z-drugs are typically more 
expensive than benzodiazepines.  We examined changes in the model for the prescription 
of z-drugs instead of benzodiazepines (estimated at CAN$ 487.00/year vs. $133.67/year 
using 2012 Pharma-care cost data from British Columbia cost saving). 
5.11. Uncertainty 
 Both deterministic and probabilistic sensitivity analysis was conducted to handle 
the uncertainty around probability of falls and fractures, probabilities of emergency room 
visit or hospitalization and cost data associated with use and consequences of use with the 
competing interventions. 
5.12. Reporting 
The results for the cost consequence analysis were reported as absolute cost saved per 
person per year. 
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Chapter 6. Methods: Cost utility analysis 
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6.1. Study Question 
To conduct the cost utility analysis for cognitive behavioral therapy over 
benzodiazepines use in older adults aged 70 years and over for treating insomnia 
6.2. Economic Evaluations chosen 
 We conducted a cost utility analysis for the two competing interventions for the 
treatment of insomnia in older adults aged 70 years and over.  Cost–utility analysis was 
developed to help decision-makers compare the value of alternative interventions that 
have very different health benefits, and it facilitates these comparisons without recourse 
to placing monetary values on different health states.  Cost–utility analysis specifies what 
value is attached to specific health states, and thus increasingly facilitates the 
transparency of resource allocation processes. 
6.3. Target Population 
 Target population of interest was older adult’s aged 70 years and older suffering 
from insomnia in Canada as of March, 2012. 
6.4. Comparators 
 A 6-week course of cognitive behavioural therapy (CBT) were compared to single 
dose of 0.5 mg. lorazepam (benzodiazepine) per day over a period of 1 year, as an 
equally effective treatment alternative for adults aged > 70 with chronic insomnia. 
6.5. Perspective 
This study was conducted from a Canadian health payer’s perspective with only 
the cost of health service resources being considered.  
6.6. Effectiveness 
 Wu et al. (156) conducted a randomised clinical trial in 2006 comparing 
cognitive-behavioural and pharmacological therapy for chronic insomnia.  Seventy-one 
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patients with chronic insomnia were randomly divided into 4 groups and either received 
cognitive-behavior therapy (CBT, n = 19), pharmacological therapy (PCT, n = 17), CBT 
plus medication (Combined, n = 18) or placebo (n = 17). The treatments lasted for 8 
weeks with follow-ups conducted at 3 and 8 months.  On the day after treatment ended, 
all patients were assessed using a polysomnography (PSG), a sleep diary and a 
psychological assessment. 
For patients on benzodiazepines, the average sleep-onset latency was 47.2 
minutes, sleep efficiency was lower than 80% and total sleep time was 368 minutes. 
There was a statistically significant difference between the two groups for sleep latency, 
total sleep time and sleep efficiency using both outcome measures (polysomnography and 
sleep diaries). However Mitchell et al. (158) reported that the quality of the evidence 
comparing benzodiazepines to cognitive behavioural therapy for insomnia in the short 
term is of very low grade, meeting 3 of 9 quality points in the GRADE system, making it 
difficult to draw firm conclusions about the superiority of CBT over benzodiazepines.  
Some meta-analysis conducted for the effectiveness of cognitive behavioral therapy and 
benzodiazepines for treating insomnia are discussed in much more details in section 3.6. 
6.7. Time Horizon 
The time horizon chosen for the model was a period of 1-year.   
6.8. Discounting 
 As the time horizon was one year, we did not discount costs associated with the 
competing interventions. 
6.9. Valuing Outcomes 
Health utilities associated with chronic insomnia vs. no insomnia and falls vs. no 
falls were derived from a comprehensive literature review and abstracted from population 
surveys or randomized controlled trials using SF-36 or EQ-5D derived algorithms for 
different sleep states, falls, fractures and fear of falling (213, 214).  Utility weights are 
shown in Table 12. 
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Table 12 Utilities associated with different health states in the cost-utility model 
1. Utility weights associated with different health states in the cost-utility model 
Health state Utility weight Variation 
lower bound 
(ref) 
Variation 
upper 
bound 
(ref) 
Standard 
deviation 
Probabilistic 
analysis 
distribution 
Insomnia treated 
with 
benzodiazepines 
0.66 0.60 (213) 0.72 (213) 0.06 Gamma 
Insomnia treated 
with CBT 
0.66 0.60 (213) 0.72 (213) 0.06 Gamma 
Untreated 
insomnia 
0.63 0.58 0.66 0.06 Gamma 
 
2. Utility weights lost due to falls and fear-of-falling used in the cost-utility 
model 
Health state Utility 
weight lost 
Variation 
lower bound 
(ref) 
Variation 
upper bound 
(ref) 
Standard 
deviation 
Probabilistic 
analysis 
distribution 
Fear of falling 0.06 0.05 (214) 0.10 (214) 0.005 Gamma 
Fall 0.03 0.02 (214) 0.04 (214) 0.005 Normal 
Fracture 0.17 0.14 (215) 0.20 (215) 0.01 Normal 
 
6.10. Study design 
A cost-utility analysis was conducted to model the quality of life outcomes and 
costs of benzodiazepine treatment for adults aged > 70 with chronic insomnia.  The 
model also determined the cost-utility of a 6-week course of cognitive behavioural 
therapy (CBT), as an equally effective treatment alternative (216).  The analysis was 
conducted from a Canadian health payer’s perspective, over a 1-year time horizon. The 
results of this cost-utility analysis are reported as incremental cost per Quality Adjusted 
Life Years (QALYs) gained.  As the time horizon is one year, we did not discount costs 
and QALYs associated with the competing interventions. 
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6.11. Modeling 
The decision tree used for the Cost Consequence Analysis was expanded to add 
the utility values for the cost utility analysis. 
6.12. Model input parameters 
6.12.1. Probability and cost data 
These are the same as described in section 5.3 for the Cost Consequence 
Analysis. 
6.12.1.1. Health utilities associated with chronic insomnia vs. no insomnia  
Health utilities associated with chronic insomnia vs. no insomnia were taken from 
a cross-sectional survey (SLEEPI-i) from 3 countries including 4067 persons in the US (n 
= 1,298; 478 good sleepers and 820 patients with insomnia), France (n = 1858; 998 good 
sleepers and 860 patients with insomnia) and Japan (n = 911; 506 good sleepers and 405 
patients with insomnia).  Web and paper-based SF-36 questionnaires were used to 
measure health related quality of life in chronic patients with insomnia and good sleepers. 
The SF-36 data were transformed into the preference-based 6-dimensional health state 
classification, the SF-6D utility scores using a well-validated algorithm.  
The SF-36 questionnaire was validated in French and Japanese but the different 
interviewing techniques used in the three countries (i.e., internet, telephone, or postal 
questionnaire) may have impacted on the responses of subjects and be associated with 
recall bias, explaining the slightly different results obtained from each country. There was 
also a sampling bias in the selection of participants as participants were recruited from an 
online panel.  This may have affected the estimates towards the null as more healthy 
participants were likely to take part in the survey and underestimation of the utility values 
lost due to insomnia may have occurred. 
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6.12.1.2. Health utilities lost due to falls vs. no falls 
Health utilities lost due to falls vs. no falls were taken a study (214) that used 
individual patient-level data from two randomised controlled trials (Hip protector study 
(217), Calcium and vitamin D study (218)) and one prospective, comprehensive, cohort 
study (219) to explore the impact of falls and fractures on HRQoL, as measured by the 
EuroQol-5D (EQ-5D).  The authors measured quality of life with a measure of utility (the 
EuroQol-5D), which allowed the burden of fear of falling to be converted to a single 
measure of HRQoL.  For the quantification of falls and fractures, the authors relied on 
self-report via postal questionnaire.   
We acknowledge that this may be a less accurate form of outcome assessment, 
subject to under or over reporting. Participation rates were also very low in these studies, 
suggesting the possibility of volunteer Potential cost saving analysis.  Finally, the results 
only apply to women. 
6.12.1.3. Health utilities lost due to hip fracture 
Utilities lost due to hip fracture were derived from EQ-5D data from a prospective 
cohort of 278 older adults (mean age 77) suffering hip fractures in Sweden (220).  In this 
cohort, a mean utility value of 0.17 (95% CI 0.14-0.20) was lost at four months post-hip 
fracture compared to pre-fracture status (Table 12).  The five health dimensions of the 
EQ-5D divide health status into 243 possible health states.  
Social tariff values for these health states, estimated as time trade off (TTO) 
utility values, were applied to the observed health states in this study.  A potential caveat 
with regard to the calculated loss of quality of life in this study was that the patients’ 
health status before fracture was retrospectively collected.  This could probably lead to 
some potential recollection bias in the respect that patients might perceive their quality of 
life to be better than it actually was which could lead to an overestimation of the loss in 
quality of life related to fracture. 
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6.13. Sensitivity analysis for the cost utility study 
Both probabilistic and deterministic sensitivity analysis were conducted to 
estimate the effect of changes in parameters on the outcome of the study.  Apart from the 
probability and cost parameters used in the cost consequence analysis, we also included 
variation in the utilities values, derived from the literature.  We included utility values for 
treated insomnia either with benzodiazepines or cognitive behavioural therapy (0.60 – 
0.66), utilities lost due to fear of falls (0.05 – 0.10), utilities lost due to falls (0.02 – 0.04) 
and utilities lost due to hip fracture (0.14 – 0.20).  All utility values used in the sensitivity 
analysis along with the references are presented in Table 12. 
6.14. Uncertainty 
 Both deterministic and probabilistic sensitivity analysis was conducted to handle 
the uncertainty around probability of falls and fractures, probabilities of emergency room 
visit or hospitalization, utilities associated with insomnia and adverse health 
consequences with the use of benzodiazepines such as falls and fractures; and cost data 
associated with use and consequences of use with the competing interventions. 
6.15. Reporting 
 The primary outcome of a cost–utility analysis is the cost per QALY, or 
incremental cost-effectiveness ratio (ICER), which is calculated as the difference in the 
expected cost of two interventions, divided by the difference in the expected QALYs 
produced by the two interventions. 
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Chapter 7. Methods: Potential cost saving analysis 
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7.1. Study Question 
 A potential cost saving analysis over a period of 5 years was conducted to 
estimate the impact of cognitive behavioural therapy compared to BDZ (lorazepam) on 
the healthcare budget, should cognitive behavioural therapy become universally 
reimbursed in Canada for seniors diagnosed with and seeking care for chronic insomnia. 
7.2. Economic Evaluations chosen 
The framework used for this analysis is depicted in Figure 2. According to Figure 2, two 
scenarios were compared in this analysis.  The first scenario was the current intervention 
mix or reference case, composed of lorazepam only while the second scenario, the new 
intervention mix, was composed of the possibility of drug treatment (lorazepam) or a 6-
week treatment with cognitive behavioural therapy. 
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Figure 2 Potential cost saving analysis framework 
 
 Since these patients would be ascribed to either lorazepam or cognitive 
behavioural therapy, two sub-populations were created.  These sub-populations were 
estimated by the product of the proportion of seniors diagnosed with insomnia, that is the 
prevalence of insomnia (105), the number of elderly individuals aged 70 years and older 
(343,000) (221), and the market share of the intervention.  As cognitive behavioural 
therapy is currently not reimbursed in Canada, no data exists on the current use of 
cognitive behavioural therapy.  We postulated that if cognitive behavioural therapy were 
reimbursed, the uptake would be gradual, at a rate of 20 % per year over a period of five 
years. 
Seniors diagnosed 
with and seeking care 
for chronic insomnia 
Current intervention 
mix (BDZ) 
New intervention mix 
(BDZ + CBT)          
20% uptake per year 
Annual financial 
impact on resource 
utilization (1) 
Annual financial 
impact on resource 
utilization (2) 
POTENTIAL 
COST 
SAVING = 
Difference in 
financial impact 
on resource use 
[(2)-(1)] 
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7.3. Target Population 
The target population is all older adults aged 70 years and older with chronic 
insomnia who could have access to cognitive behavioural therapy.  No current literature 
exists on the current use of cognitive behavioural therapy in Canada but in the United 
States, only 11 % of patients received cognitive behavioural therapy for anxiety, while in 
Great Britain, only 5 % to 15 % of patients received counseling of any kind (222). The 
assumption is that coverage will be accessible to all eligible candidates after provincial 
reimbursement change.  The proportion of patients diagnosed with insomnia will be 
multiplied by the number of elderly individuals aged 70 years and older between 2012 
and 2016 and by the rate of patients covered (assumed to be 100%).   This calculation 
will result in the total number of patients eligible for treatment of insomnia 
7.4. Perspective 
 The potential cost saving analysis was performed according to the Canadian 
health payer’s perspective.  According to this perspective, all costs included in the Cost 
consequence analysis were considered in this analysis. 
7.5. Time Horizon 
The time horizon chosen for the model was a period of 5 years with a base case of 
2012.  
7.6. Cost Valuation for the potential cost saving analysis 
The potential cost saving analysis was performed according to the Canadian 
health payer’s perspective.  According to this perspective, all costs included in the Cost 
consequence analysis were considered in this potential cost saving analysis.  The costs 
considered were: drug acquisition cost, doctor visit costs and the cost of falls associated 
with the different competing interventions.  After adding these costs, the total cost per 
year for each patient suffering from insomnia was obtained.   
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For the current intervention mix, the total cost per year for each patient suffering 
from insomnia (case) was obtained by adding the following costs: drug acquisition costs 
per case per year, doctor visit cost per case per year and cost of drug-induced falls per 
case per year.  Then, the total costs per year for each patient was multiplied by the size of 
the sub-population ascribed to lorazepam.  The same reasoning was applied to the 
calculation of the annual financial impact on resource use for the new intervention mix.  
The budgetary impact of reimbursing cognitive behavioural therapy was ascertained by 
subtracting the total cost generated by cognitive behavioural therapy from that of 
lorazepam.  The temporal framework was 5 years with 2012 as the base year.  
The financial impact on resource use of both scenarios was calculated annually.  
For every fiscal year, the potential cost saving analysis estimation consisted in deducting 
the financial impact on resource use of the current intervention mix from that of the new 
intervention mix. To obtain the 5-year potential cost saving analysis estimate, we 
summed the 1-year potential cost saving analysis estimates from 2012 to 2016.     
Some assumptions made in this potential cost saving analysis must be highlighted.  
The population modeled was assumed constant over the temporal framework.  The 
rationale underlying this assumption was that entry into the cohort would be 
counterbalanced by the mortality rate in the same group, over the 5-year period.  
It was postulated that the potential cost saving analysis would start the year that 
cognitive behavioural therapy would be reimbursed and the pre– cognitive behavioural 
therapy market condition would consist only of lorazepam.  The model assumes that 
increased use of cognitive behavioural therapy would result in a drop in lorazepam use 
with a gradual cognitive behavioural therapy uptake of 20% per year over 5 years.  The 
model also assumes that a 6-week course of cognitive behavioural therapy would only be 
delivered once to each individual, with the effects sustained indefinitely. 
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7.7. Sensitivity analysis for potential cost saving analysis 
In univariate sensitivity analysis, we tested four parameters: the base case 
expected incidence of falls, the impact of an annual increase in insomnia, varying uptake 
of cognitive behavioural therapy, and the cost of pharmacologic treatment.  No studies 
were identified that provided evidence on the incidence of chronic insomnia in the 
elderly.  For the sensitivity analyses we therefore used a 7.4% annual incidence rate for 
insomnia syndrome from a population based study with a mean age of 45 years (223).  
Data for this study were derived from a large epidemiological study conducted in 
the province of Quebec, Canada (aged 18 years and over).  The authors conducted a 
telephone and postal survey to document the prevalence of insomnia and determinants of 
health-seeking behaviors. The one-year incidence rate of 7.4% for insomnia was 
multiplied by the size of the target population and added to the annual prevalence rate of 
insomnia in elderly population to obtain the economic impact of the intervention.   
Since no data exists in Canada for the utilization of cognitive behavioural therapy 
for treating insomnia in elderly, we postulated an estimate of 20% utilization of cognitive 
behavioural therapy for the base case. We tested the impact of an annual increase of 10 to 
30% uptake of cognitive behavioural therapy on the provincial budget.  We also 
conducted sensitivity analysis for the variation in the base case probability of falls within 
a range of 0.20 to 0.40.  The cost of pharmacological therapy was also varied from least 
expensive (generic benzodiazepine agents) to most expensive (brand name Z-drug non-
benzodiazepine alternates costing CAD$ 582 per person per year including consultation 
fees) (203).  This was done for the reason that most prescribers are switching to 
prescription of benzodiazepine-like drugs instead of benzodiazepines, which are more 
costly than benzodiazepines. 
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Chapter 8. Results 
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8.1. Results for the cost consequence analysis 
8.1.1. Base case analysis 
The results of the cost consequence analysis are shown in Table 13.  When health 
care resources due to falls are not considered in the analysis, benzodiazepine treatment 
costs 30% less than the price of cognitive behavioural therapy (CAN $231 vs. CAN $335 
per individual per year).  However, when the cost of falls is considered, the cost of 
cognitive behavioural therapy becomes 13% less than benzodiazepine treatment. The cost 
and utilities associated with treatment before and after considering the costs of falls are 
provided in Table 13 (absolute cost-saving CAN$ 177 per person per year respectively, 
CAN $1357 vs. $1180). 
Table 13 Cost and utilities associated with the treatment of geriatric insomnia before 
and after considering the risk of falls 
 Without consideration of fall-related 
adverse events 
Consideration of fall-related adverse 
events 
 Cost/person/year Utilities Incremental 
Value 
(CAD $) 
Cost/person/year 
+ 
cost/person/fall-
related ADE 
Average 
utilities 
 
Treatment with 
BDZ 
$ 231 0.66 104 (in favor 
of BDZ) 
$ 1,357 0.63 0 
Treatment with 
CBT 
$ 335 0.66 0 $ 1,180 0.64 $177 (in 
favor of 
CBT) 
 
8.1.2. Results for sensitivity analysis 
We conducted both deterministic and probabilistic sensitivity analyses to observe 
the effect of varying parameters on the outcome of the analysis.  A tornado diagram 
shows the most influential parameters that have the most impact on the outcome in 
univariate deterministic sensitivity analyses (Figure 3). In the tornado diagram the 
horizontal axis is the outcome; along the vertical axis, parameters are arrayed and 
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horizontal bars represent the outcome range associated with the specified parameter’s 
range.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 3 Deterministic sensitivity
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 analyses for Cost Consequence Analysis 
 
78 
 
The outcome point estimate corresponding to base-case values is indicated by a 
vertical line cutting through all horizontal bars.  The longest bar (reflecting the parameter 
generating the widest uncertainty) is placed at the top, and the other bars are arrayed in 
descending order of length.  Thus, the deterministic sensitivity analysis for the Cost 
Consequence Analysis shows that the variation in the probability of hip fracture has the 
highest impact on the outcome of the analysis while the probability of falls with 
benzodiazepines ranks second.   
The costs of general practitioner visit ranked third.  The results of the probabilistic 
sensitivity analysis report for the cost consequence analysis are presented in section 
12.1.1. The probabilistic sensitivity analysis report shows that even at different varying 
parameters, benzodiazepines cost CAD$ 1,342, S.D $ 577 (range 252-3,764) on average 
per person per year vs. CAD$ 1,159, S.D $ 524 (range 349-2,828) on average per person 
per year for cognitive behavioural therapy; thus saving an average of CAD$ 183 per 
person per year when the cost of falls are considered across all provinces in Canada. 
Results for the changes in the model for the prescription of benzodiazepine-like 
drugs (Z-drugs) instead of benzodiazepines are presented in Figure 4 . The result shows 
that benzodiazepines are cost saving compared to cognitive behavior therapy at a 
minimum 0.08 probability of falls in the elderly.  As shown in the figure, the cost savings 
from cognitive behavioural therapy increase as the cost of the pharmacological 
intervention increases and cost savings reach their highest level with branded Zopiclone 
with an estimate of nearly CAD$ 301 saved per person per year in favor of cognitive 
behavioural therapy in a population with even at a minimum 0.08 risk of falling. 
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Figure 4 Graph showing absolute cost saving versus base case probabilities of falls 
 
      Zopiclone (Generic) = CAD$=204.67/year 
Zopiclone (Brand) = CAD$=487.00/year 
8.2. Results for cost utility analysis 
8.2.1. Base case analysis 
The results of the cost-utility analysis are shown in section 12.1.2.  When 
cognitive behavioural and benzodiazepine treatment are considered without fall-related 
consequences, the health utility associated with treated insomnia in both instances is 0.66, 
which is not surprising since the two therapies appear to be equally efficacious, yielding 
similar health states.  However when falls are considered, the utility associated with 
benzodiazepines is 0.63, while for CBT it is 0.64. The average cost effectiveness for 
benzodiazepines becomes CAN $ 2,147 while for cognitive behavioural therapy it 
becomes CAN $ 1,845, showing that benzodiazepines were dominated. (see page 108) 
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8.2.2. Results for sensitivity analysis  
We conducted both deterministic and probabilistic sensitivity analyses to observe 
the effect of varying parameters on the outcome of the analysis.  Apart from uncertainty 
in probability and cost parameters used in the Cost Consequence Analysis, we also 
included variation in utilities values due to falls, fear of falls and fractures in geriatric 
patients. The deterministic sensitivity analysis in the form of a tornado diagram is 
presented in Figure 5. 
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100% (completely replacing lorazepam therapy), the expected annual direct cost savings 
for the treatment of insomnia would be $ 441.00 million CAD dollars, with a cumulative 
cost savings of $112.00 billion CAD dollars over the 5-year potential cost saving analysis 
temporal framework due to prevention of drug-induced falls and fall-related 
consequences. 
Table 14 Potential cost saving  
  Reference 2012 2013 2014 2015 2016 
Estimated size of target 
population (constant) 
343,000 343,000 343,000 343,000 343,000 343,000 
CBT uptake 
BDZ 100% 80% 60% 40% 20% 0 
CBT 0 20% 20% 20% 20% 0,2 
Direct medical costs 
without ADE(in millions 
CAD$) 
79.20 86.40 70.50 54.70 38.80 22.90 
Falls related costs (in 
millions CAD$) 
465.40 453.30 360.20 267.10 174.00 80.90 
Total direct costs 
attributable to the 
management of chronic 
insomnia (in millions 
CAD$) 
544.70 539.70 431.00 321.80 212.80 103.90 
Annual savings due to - 5.10 113.90 222.80 331.90 441.00 
reimbursement of CBT 
(in millions CAD$) 
 
BDZ: Benzodiazepines CBT: Cognitive Behavioural Therapy 
 
8.3.2. Results for the univariate sensitivity analysis 
The overall results for the sensitivity analyses for the potential cost saving analysis are 
presented in Table 14 .  The univariate sensitivity analysis shows that the application of a 
7.4 % annual incidence in the rate of seniors with chronic insomnia and a change in 
cognitive behavioural therapy uptake rate have an important impact on the estimated 
cost-savings (Table 15).  As anticipated, the projected total savings per year is positively 
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correlated with the application of the incidence rate of chronic insomnia and the increase 
in the uptake of cognitive behavioural therapy, which in turn is associated with the most 
important cumulative cost savings as shown in Table 16 ($713 million Can dollars).  
Table 15 Sensitivity analysis for the potential cost saving  
 parameter 
Budget impact results expressed in Canadian dollars  
(in millions CAD$) 
2012 2013 2014 2015 2016 Total 
Market share 
(in 
percentage) 
Lorazepam 
 
80% 60% 40% 20% 0  
CBT 20% 20% 20% 20% 0,2 
Base case results, cost 
saved (in millions CAD$) 
- 5.10 113.90 222.80 331.90 441.00 1,121.00 
Incidence rate of chronic 
insomnia 
 
7.4% increase 
annually 
5.10 113.00 103.00 152.00 340.00
 
713.00 
 
Uptake of CBT 
10% 2.50 5.70 11.10 16.50 28.40 64.20 
30% 7.51 170.90 334.30 492.70 544.60 1,549.91 
Base case probability of 
falls 
0.20 0.12 87.00 172.80 258.60 344.50 863.02 
0.40 6.90 137.20 267.40 397.60 527.80 1,336.80 
Cost of pharmacotherapy 
[Zopiclone (branded)] 
(including G.P consultation) 
 
 
 
CAD$ 582 
 
 
5.80 
 
218.60
 
378.60
 
538.50 
 
698.40
 
 
1,839.90 
 
CBT: Cognitive Behavioural Therapy 
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Table 16  Sensitivity analysis results at the incidence rate of 7.4 % increase annually 
    
      
  Reference 2012 2013 2014 2015 2016 
Estimated size of target 
population (constant) 
 
343,000 
 
343,000 
 
559,000 
 
598,000 
 
640,000 
 
684,000 
CBT uptake 
BDZ 100% 80% 60% 40% 20% 0 
CBT 0 20% 20% 20% 20% 0.2 
Direct medical costs 
without ADE (in millions 
CAD$) 
79.20 86.30 70.50 89.10 67.70 42.80 
Falls related costs (in 
millions CAD$) 465.40 453.30 587.15 465.80 324.70 161.60 
Total direct costs 
attributable to the 
management of chronic 
insomnia (in millions 
CAD$) 
544.60 539.60 657.60 555.00 392.50 204.50 
Annual savings due to 
- 5.10 112.90 103.30 152.10 340.00 reimbursement of CBT 
(in millions CAD$) 
 
  On the contrary, the cumulative cost savings decrease to its lowest value when 
cognitive behavioural therapy uptake is only 10 % as shown in Table 17 64.2 million Can 
dollars) and maximum when uptake is 30% as shown in Table 18 (155 billion CAD$).  
As we can see in Table 19, even at a lesser base case of probability of falls (0.20), 
cognitive behavioural therapy saves a total of 86 billion dollars over a period of five 
years.  As expected, an increase in the base case probability of falls (0.40) and an 
increase in the cost of pharmacotherapy (CAD$ 582 per person per year for branded 
Zopiclone) results in a huge impact on budgetary saving of $134 and $184 billion CAD 
over a period of five years (Table 20 and Table 21) 
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 Table 17  Sensitivity analysis results at the CBT uptake rate of 10% annually 
  
  Reference 2012 2013 2014 2015 2016 
Estimated size of target 
population (constant) 
343,000 343,000 343,000 343,000 343,000 343,000 
CBT uptake 
BDZ 100% 90% 80% 70% 60% 0 
CBT 0 10% 10% 10% 10% 0,5 
Direct medical costs 
without ADE (in millions 
CAD$) 
79.20 82.80 74.80 66.90 59.00 57.40 
Falls related costs (in 
millions CAD$) 465.40 459.30 412.80 366.20 319.70 202.30 
Total direct costs 
attributable to the 
management of chronic 
insomnia (in millions 
CAD$) 
544.60 542.10 487.70 433.20 378.70 259.80 
Annual savings due to 
- 2.50 5.70 11.10 16.50 28.40 reimbursement of CBT (in 
millions CAD$) 
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Table 18 Sensitivity analysis results at the CBT uptake rate of 30% annually 
  Reference 2012 2013 2014 2015 2016 
Estimated size of 
target population 
(constant) 
343,000 343,000 343,000 343,000 343,000 343,000 
CBT uptake 
BDZ 100% 70% 40% 10% 0% 0 
CBT 0 30% 30% 30% 10% 0 
Direct medical costs 
without ADE(in 
millions CAD$)  
79.20 89.90 66.10 42.30 11.40 0 
Falls related costs (in 
millions CAD$) 
465.40 447.20 307.60 167.90 404.70 0 
Total direct costs 
attributable to the 
management of 
chronic insomnia(in 
millions CAD$)  
544.60 537.10 373.70 210.30 519.60 0 
Annual savings due to 
- 7.51 170.90 334.30 492.70 544.60 reimbursement of 
CBT (in millions 
CAD$) 
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Table 19 Sensitivity analysis results with 0.20 base case probabilities of falls  
 
  Reference 2012 2013 2014 2015 2016 
Estimated size of 
target population 
(constant) 
343,000 343,000 343,000 343,000 343,000 343,000 
CBT 
uptake 
BDZ 100% 80% 60% 40% 20% 0 
CBT 0 20% 20% 20% 20% 0.2 
Direct medical 
costs without 
ADE(in millions 
CAD$)  
79.20 86.30 70.50 54.60 38.80 22.90 
Falls related 
costs(in millions 
CAD$)  
349.80 341.40 271.50 201.50 131.50 61.60 
Total direct costs 
attributable to the 
management of 
chronic insomnia 
(in millions CAD$) 
429.00 427.80 342.00 256.20 170.40 84.50 
Annual savings 
due to 
- 0.12 87.00 172.80 258.60 344.50 reimbursement of 
CBT (in millions 
CAD$) 
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Table 20 Sensitivity analysis results with 0.40 base case probabilities of falls 
  Reference 2012 2013 2014 2015 2016 
Estimated size of 
target population 
(constant) 
343,000 343,000 343,000 343,000 343,000 343,000 
CBT 
uptake 
BDZ 100% 80% 60% 40% 20% 0 
CBT 0 20% 20% 20% 20% 0.2 
Direct medical 
costs without ADE 
(in millions CAD$) 
79.20 86.30 70.50 54.60 38.80 22.90 
Falls related costs 
(in millions CAD$) 571.70 557.60 443.20 328.90 214.50 100.20 
Total direct costs 
attributable to the 
management of 
chronic insomnia 
(in millions CAD$) 
651.00 644.00 513.80 383.60 253.40 123.20 
Annual savings due 
to 
- 6.90 137.20 267.40 397.60 527.80 reimbursement of 
CBT (in millions 
CAD$) 
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Table 21 Sensitivity analysis results with increased cost of pharmacotherapy  
  Reference 2012 2013 2014 2015 2016 
Estimated size of 
target population 
(constant) 
343,000 343,000 343,000 343,000 343,000 343,000 
CBT uptake 
BDZ 100% 80% 60% 40% 20% 0 
CBT 0 20% 20% 20% 20% 0.2 
Direct medical costs 
without ADE (in 
millions CAD$) 
199.60 182.60 142.70 102.80 62.90 22.90 
Falls related costs (in 
millions CAD$) 599.90 558.00 438.00 318.00 198.10 78.10 
Total direct costs 
attributable to the 
management of 
chronic insomnia (in 
millions CAD$) 
799.50 740.70 580.80 420.90 261.00 101.10 
Annual savings due to 
- 5.80 218.60 378.60 538.50 698.40 reimbursement of 
CBT (in millions 
CAD$) 
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Chapter 9. Discussion 
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The economic analysis presented in this paper indicates that although 
benzodiazepines are inexpensive, they carry substantial hidden costs in increased health 
care resources attributable to falls in the elderly.  The results of the sensitivity analyses 
suggest that cognitive behavioural therapy is almost always cost-saving, and variation in 
the input parameters for the model do not significantly affect this finding; only the 
magnitude of the savings with cognitive behavioural therapy changes. Falls not only 
incur monetary loss, but also lead to diminished quality of life.  The result with 
benzodiazepine treatment is increased cost for a net reduction in quality of life for the 
geriatric population with insomnia.   
Findings from the economic analysis revealed that when falls are not considered, 
benzodiazepine therapy costs 13% less per individual than cognitive behavioural therapy 
and when the cost of falls attributable to benzodiazepine use is considered, cognitive 
behavioural therapy emerges as a cost-saving strategy, saving the health care system 
CAN $177 per year per person treated for insomnia (CAN $1,357 for benzodiazepines vs. 
$1,180 for cognitive behavioural therapy).  Probabilistic sensitivity analyses suggest that 
even at different varying parameters, benzodiazepines cost CAD$ 1,305, S.D $ 598 
(+245-2,625) on average per person per year vs. CAD$ 1,129, S.D $ 514 (+342-2,526) on 
average per person per year for cognitive behavioural therapy when the cost of falls are 
considered in geriatric populations.  Cognitive behavioural therapy dominates 
benzodiazepines in geriatric patients when the cost of falls is considered.   
One of the greatest challenges in preparing the economic model for this analysis 
was selection of the parameters to populate the decision tree.  While the 30% baseline 
prevalence of falls in the elderly is fairly well recognized, and easily subject to 
modification in sensitivity analyses, the degree to which benzodiazepines increase the 
risk of falls over baseline was more difficult to establish with certainty.  Two recent well-
conducted meta-analyses suggest that indeed a strong association between 
benzodiazepine use and the risk of falling exists for older adults (60, 61).  Woolcott et al. 
reported a pooled OR of 1.57 (95% CI 1.43-1.72) while Bloch et al. reported an OR of 
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1.39 (1.24-1.54) for benzodiazepines.  However, which exact value to choose for the 
economic analyses required much scrutiny and debate. 
Woolcott et al (60) used Bayesian methodology while Bloch F et al. (61) used a 
frequentist approach for their meta-analysis.  There were 11 studies in the Woolcott meta-
analysis that included benzodiazepine use and risk of falling in older adults, out of which 
6 were conducted among community dwelling older adults.  The authors report the OR 
for the total group of 20,652 participants, of which 8,704 participants resided in long term 
care or the acute care hospital setting (i.e. 60% community individuals).  
The mean age for the sample was 77 years.  Unfortunately Woolcott et al. did not 
report tests of homogeneity for their meta-analysis; however various estimates of 
association were similar.  For instance, the OR using prior evidence was 1.48 (1.23-1.77), 
for the Bayesian pooled estimate 1.57 (1.43-1.72) and for a random effects model 1.60 
(1.46-1.75). Only the smallest of the six studies that included community dwelling adults 
had a lower limit of the confidence interval that crossed 1. The other five were well 
above 1. The authors did conducted stratified analyses by setting and stated that there was 
no significant difference in the OR for the risk of benzodiazepines and falls by setting, 
but the exact results were not reported. 
There were 14 studies included in the Bloch et al. meta-analysis examining the 
use of benzodiazepines and the risk of falls. The authors report a pooled OR of 1.39 
(1.24-1.54) for the entire sample of 20,576 individuals but present a stratified analysis by 
setting which showed a pooled OR of 1.61 (1.35-1.93) for persons living in institutions 
(n=9 studies), and an OR of 1.27 (1.11-1.46) for a group of 5 studies that reported 
“ambulatory or both” settings. No details were provided on how the authors made this 
distinction. The Bloch et al. group showed that the risk of falls decreased for individuals 
aged > 80, which runs counter to many other studies. Furthermore the analysis for the 
“ambulatory or both” group showed an I2 value of greater than 50%, suggesting that there 
was marked heterogeneity within this group. This further reduced our confidence in the 
estimate of the OR of 1.27 (1.11-1.46) for community-dwelling adults. 
95 
 
There were also methodological differences between the two meta-analyses for 
the ascertainment of falls and medication use.  Bloch et al. analyzed psychotropic drugs 
as a single class and also as individual classes of drugs.  Falls were predominantly 
ascertained by self-report.  Woolcott et al. ascertained falls by incident report in hospital 
or by recall. Medications were ascertained at baseline or by interview. Overall, because 
our population of interest was community dwelling elderly we used the Bayesian pooled 
estimate for the increased risk of falls from benzodiazepine use from the Woolcott et al. 
meta-analysis (OR 1.57), but in order to account for uncertainty, we enlarged the bounds 
of confidence interval (1.23 -1.77) from the Bloch et al. study. 
It could be argued that the resultant health state attributable to treatment of 
insomnia with benzodiazepines (0.63) compared to the health state attributable to 
treatment with cognitive behavioural therapy (0.64) is not significantly different. If so, 
the analysis presented in this thesis could be viewed as a non-inferiority analysis. The 
conclusion remains the same: although there is no significant gain in overall health state 
to the elderly by offering cognitive behavioural therapy for the treatment of insomnia, 
substantial cost savings result in terms of diminished health care resource use due to 
drug-induced falls.  
Cost estimates for adverse events associated with the use of benzodiazepines for 
the treatment of insomnia were calculated in the year 2009, and these costs were inflated 
to 2012 CAD$ using the consumer price index (210).  Using these manipulations in the 
potential cost saving analysis, substitution of non-pharmacologic management over drug 
therapy for geriatric insomnia emerged as a cost-effective fall prevention strategy. The 
effectiveness of the strategy rose proportionate to increases in expected fall rates, for 
example in frail older adults living in residential or long-term care, or in high risk 
previous fallers. The effectiveness of the strategy also rose proportionate to the cost of 
the type of medication used to treat insomnia.   
The probabilistic sensitivity analysis report shows that even at different varying 
parameters cognitive behavioural therapy has a net monetary benefit of CAD$ 30,844 
with equivalent utilities.  The cost effectiveness acceptability curve shows that cognitive 
behavioural therapy is 97 % cost effective at 30,000 CAD $ of willingness to pay and 
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100% cost effective at any value of willingness to pay from CAD$ 60,000 to CAD$ 
100,000.  Based on our potential cost saving analysis, if reimbursement of cognitive 
behavioural therapy were to result in a 20% market share of treatment for insomnia 
during the first year, reimbursement of CBT would result in a cost-savings of 
approximately 5.5 million Canadian dollars due to fall-related savings, compared to the 
current scenario where only benzodiazepines are reimbursed.  In 2016, if the CBT market 
share were to increase up to 100% (completely replacing lorazepam therapy), the 
expected annual direct cost savings for the treatment of insomnia would be $ 441 million 
CAD dollars, with a cumulative cost savings of $112 billion CAD dollars over the 5-year 
potential cost saving temporal framework due to the prevention of drug-induced falls and 
fall-related consequences.   
Practical implications of our findings point to the wisdom of discontinuing 
benzodiazepines in all chronic users and substituting cognitive behavioural therapy as 
treatment for insomnia.  We recognize this may not be a realistic solution, especially 
given the current reimbursement scenario. Furthermore, discontinuation of 
benzodiazepine therapy is known to be difficult among long-term consumers, despite 
evidence suggesting that chronic use is no longer associated with improved sleep quality 
in the elderly (224, 225). Physicians also tend to minimize benzodiazepine-associated 
adverse effects, anticipate withdrawal failure, and wish to avoid patient resistance (225).  
Nonetheless, discontinuation of benzodiazepines is certainly possible, as has been 
documented as a result of physician interventions that highlight the risk of injury in 
certain patients.  Robyn Tamblyn et al.  (226)  conducted a cluster randomized controlled 
trial of 81 family physicians and 5628 of their patients aged 65 and older who were 
prescribed psychotropic medication.  The authors concluded that the intervention reduced 
the risk of injury by 1.7 injuries per 1,000 patients (95% CI 0.2/1000 to 3.2/ 1,000; p= 
0.02).  Hoebert et al. (227) conducted a retrospective observational database study in 
Netherland using electronic health records–based Netherlands Information Network of 
General Practice (LINH) using 13,596 patients. The authors concluded that a 
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reimbursement restriction on benzodiazepine use in patients with newly diagnosed 
sleeping disorder was lower in the first 2 to 3 quarters after the policy change.  
As Medicare Part D excludes benzodiazepine medications from coverage, and 
some state Medicaid programs in United States also limit coverage, Briesacher et al. 
(228) conducted a quasi-experimental study that included 1 068, 104 residents from 48 
states.  The authors concluded that no supplemental coverage for benzodiazepines 
reduced the utilization of benzodiazepines.  The no-supplemental-coverage policy 
resulted in an immediate and significant reduction of 10 absolute points in 
benzodiazepine use (27.0% to 17.0%) after Medicare Part D was implemented (95% 
confidence interval, -0.11 to -0.09; P < .001). Of note, benzodiazepine use remained 
stable in the partial-supplemental- and complete-supplemental-coverage states. 
Baillargeon et al. (229) conducted a randomized controlled trials using 344 participants, 
(mean age 67.4 years) randomly assigned to undergo cognitive-behavioural therapy plus 
gradual tapering of the drug (combined treatment) or gradual tapering only. The authors 
concluded that offering a 6-week course of cognitive behavioural therapy has been shown 
to effectively allow patients to transition to better sleep habits during a gradual tapering 
protocol. 
Formal health economic analyses of cognitive behavioural therapy in Canada are 
lacking. Even if available, the channels for submission of this evidence are difficult to 
determine.  This situation contrasts with the clearly defined procedures for medications, 
which are evaluated via the Common Drug Review process (Canadian Agency for Drugs 
and Technologies 2009).  This thesis responds to the demand for further evaluation of the 
economic benefits of cognitive behavioural therapy in the elderly by health technology 
assessment organizations in Quebec such as L'Institut national d'excellence en santé et en 
services sociaux (INESSS) and the Canadian Agency for Drugs and Technologies 
(CADTH) in Canada. 
This is the first Canadian study looking at the economic impact of fall-related 
consequences in the drug management of chronic insomnia in seniors aged 70+.  To our 
knowledge, this type of “geriatric-oriented” economic analysis has previously never been 
attempted.  It sets the precedent for investigating the economic impact of other drugs 
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known to incur falls or other non-traditional geriatric syndromes (confusion, 
incontinence) in the elderly.  Hopefully, we will build a growing body of evidence 
showing that the reimbursement of non-pharmacological therapy is equally, if not more 
important, for seniors at risk of functional decline in their later years of life.  
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Chapter 10. Limitations 
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Decision-tree analysis is the simplest form of modeling technique, quick and easy 
to generate results, but is considered limited for chronic disease management.  We used a 
decision tree in our economic analysis because various input parameters like cost and 
utilities associated with insomnia in older adults are scarce and the available studies 
provided data for a maximum time period of 1 year only.  Although a Markov model 
could have potentially provided more information about insomnia remission and 
treatment, we did not have valid data to populate such a model and decided it was 
preferable to restrict the analysis to a 1-year decision tree.  
Some of our assumptions also underestimated the complexity of our analysis.  We 
assumed that the risk of falls with cognitive behavioural therapy equaled that of the 
general population and that there was no incremental risk of falls with cognitive 
behavioural therapy.  We also assumed that there would be complete adherence of 
patients for cognitive behavioural therapy and BZD treatments. These assumptions may 
be unrealistic. We also did not look at the possibility of recurrent falls during the one-
year time period, nor recurrence of insomnia after cognitive behavioural therapy.  
We limited our analysis to the occurrence of falls due to benzodiazepine use, 
however, there are many other adverse events associated with the use of benzodiazepines 
in the elderly people such as cognitive impairment and motor vehicle accidents.  We only 
accounted for falls and fractures, thus underestimating the real cost saved by the use of 
cognitive behavioural therapy for the treatment of insomnia in the elderly.  We did not 
include cognitive impairment as it is difficult to quantify its impact, and we did not 
include automobile crashes as many older persons no longer drive.   
We also did not model the possibility of death in the model, which could have 
occurred post-surgery for hip fracture or due to head trauma after a fall. Nor did we 
include the costs of nursing home admission after hip fracture. This lack of data to 
populate the model increases uncertainty around the cost-utility analysis and the potential 
cost saving analysis, in the direction of underestimation of the costs due to 
benzodiazepine-induced falls.   
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Cost of medication acquisition, dispensing fees and general physician visit were 
taken from directly from the Ministry of Health website and represent an accurate 
estimation of medication cost. Cost of Psychologists visit were taken from the 
psychological association of the British Columbia and thus represent only an estimate but 
results were generalized for Canada by conducting sensitivity analysis for the lower and 
highest drug acquisition cost, GP visit and psychologist visit for different provinces in 
Canada.  Cost of adverse consequences resulted from the use of benzodiazepines were 
taken from a single study and were presented for the year 2009.  We inflated that cost for 
the year 2012 by using consumer price index (ref.).  There is a great variation in the 
health resource cost between the provinces in Canada, so we collected aggregate per diem 
cost for different provinces for Canada and difference for the highest and lowest province 
price were inflated to the 2012 cost.  
QALYs for the insomnia versus no insomnia were taken using SF-36 validated 
questionnaire but there was a sampling Potential cost saving analysis in the selection of 
participants as participants were recruited from an online panel.   This may have affected 
the estimates towards the null as more healthy participants were likely to take part in the 
survey and underestimation of the utility values lost due to insomnia may have occurred.  
For the quantification of utilities lost due to falls, the authors relied on self-report via 
postal questionnaire; we acknowledge that this may be a less accurate form of outcome 
assessment, subject to under or over reporting.   
Participation rates were also very low in these studies, suggesting the possibility 
of volunteer Potential cost saving analysis. Finally, the results only apply to women. 
Utilities lost due to fractures were estimated by the time trade off (TTO) method and 
comparison to a health state before the fracture and these data were retrospectively 
collected.  This could probably lead to some potential recall bias in the respect that 
patients might perceive their quality of life to be better than it actually was which could 
lead to an overestimation of the loss in quality of life related to fracture.  Probability 
values for falls. fractures, emergency room visit and hospitalization with two 
interventions as well as with insomnia itself were taken after a literature search and any 
uncertainty around the estimates were resolved by using a wide range for input 
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parameters used in sensitivity analysis.  Despite all these limitations, we believe that our 
model clearly captures the fact that substantial cost-savings could occur if cognitive-
behavioural therapy were to replace drug-therapy for the treatment of insomnia.  
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Chapter 11. Conclusion and future directions 
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In conclusion, this case example illustrates that the current treatment 
reimbursement options that fund pharmacologic therapy instead of non-pharmacologic 
therapy for geriatric insomnia are neither cost-saving nor ethically recommendable from 
the health system’s perspective.  Perceived as more expensive and resource intensive, 
non-pharmacologic therapies are actually cost saving by preventing falls, fractures and 
hospitalizations.  In the future both clinicians and decision-makers need to consider 
restructuring their decision-making process for prescribing, renewing and reimbursing 
benzodiazepine therapy for chronic insomnia in the elderly.  More studies in this area 
would be greatly welcome and might help the shift from pharmacologic to non-
pharmacological therapies. 
Other medications, chronic conditions and geriatric syndromes should be 
analyzed to add to a growing body of evidence that reimbursement of non-pharmacologic 
therapies should be considered to treat chronic conditions in the elderly.  For 
benzodiazepines in particular, it would be interesting to find a way to account for all 
adverse events including falls, fractures, cognitive impairment and motor-vehicle 
accidents in order to estimate the overall health burden for using benzodiazepines in the 
elderly for treating insomnia.  Longer clinical studies are also needed on the long-term 
effectiveness of cognitive behavioural therapy in order to account for repeated treatment 
rates in the Potential cost saving.  
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